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Abstract
Osteopontin (OPN) is a multi-functional protein that can influence cell
survival, chemotaxis and inflammation. The role of OPN produced by kidney tubular
epithelial cell (TEC) following transplantation has not been defined. This study tests
the role of OPN on the chemotaxis of Natural Killer (NK) cells, as well as the role of
OPN as a survival factor for TECs in vitro and in vivo following kidney
transplantation.
OPN-/- TECs had a substantially reduced capacity to attract NK cells in vitro
when compared with OPN+/+ TECs. OPN may only be an indirect regulator for the
expression of NK specific chemokines in TECs, since recombinant mouse OPN had
no direct chemotactic effect on NK cell migration. OPN did not alter survival of TECs
when exposed to lethal doses of TNF-a, IFN-y and hypoxia.
Kidneys from OPN-/- mice (C57BL/6) were transplanted into MHC
mismatched (Balb/c) nephrectomized recipients. OPN-/- kidney donor grafts
resulted in significantly reduced survival and function when compared to OPN+/+
grafts. While the absence of OPN improves kidney ischemia reperfusion injury,
possibly through an indirect effect on NK cell chemotaxis, the elimination of kidney
expressed OPN may not benefit transplantation.

Keywords: Tubular epithelial cell, osteopontin, chemotaxis, cell death, kidney
transplant
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1. Introduction
1.1.

Chronic Kidney Disease, Dialysis and Transplantation
The kidney is a multi-functional organ that primarily provides homeostasis

to the body by filtering the blood and hence, regulating its pH, pressure, and
electrolytes. The kidney produces urine as a result of blood filtration and thus
removes urea and ammonium. Generally, kidney function is assessed clinically by
the repeated measurement of serum levels of creatinine and blood urea nitrogen
(BUN), which are normally filtered and removed by kidneys. Thus patients with
deteriorating kidney function accumulate higher levels of both, in addition to
acidosis and increased potassium. Furthermore, the kidney is also part of the
endocrine system by producing hormones such as calcitriol (vitamin D), renin and
erythropoietin (EPO). Calcitriol, renin and EPO are hormones used to maintain the
homeostasis of blood calcium levels, mean arterial blood pressure, and red blood
cell mass respectively. If kidney function ceases to operate, not only are the above
mentioned functions altered, but there is also an immediate accumulation of toxic
metabolic end-products. Toxins that build up in the blood during kidney failure
include protons (acidosis), hypoxanthanine, lactate and many others. Therefore, the
loss of kidney function results in the accumulation of toxins, inability to excrete
water, anemia, severe fatigue, loss of energy, and loss of appetite.

Due to its

importance in maintaining health, severe kidney damage often requires immediate
treatment to prevent death.
Kidney injury has diverse etiologies and includes hypertension, diabetes,
glomerulonephritis, autoimmunity and toxic injury from drugs and infections. If
severe enough, kidney injury leads to end-stage renal failure with a requirement for
dialysis or transplantation. Dialysis replaces the kidney function of waste removal
via diffusion and fluid removal by ultrafiltration. However, dialysis is unable to
replicate the kidney's endocrine function to produce hormones which can only be
replaced via exogenous administration.

Dialysis, if required for severe kidney

failure, is clearly disruptive to everyday life and is regarded by most to be a
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transition stage for kidney transplantation in select patients that can undergo the
procedure.
More than 50% of the approximate 4000 patients currently waiting for
transplantation in Canada are on dialysis [1].

Although transplantation is the

optimal therapy for kidney replacement with improved survival and greater quality
of life in patients medically suitable for transplantation, the number of available
kidneys limits transplantation as an option. As a result many patients must remain
on dialysis. Dialysis, while life saving, is also associated with accelerated cardiac
complications, infections, and a shortened life span [2]. In contrast, a study had
shown that the survival of dialysis patients versus survival of transplant patients
increases by 30 to 40% after a successful kidney transplant [3]. Dialysis is not only
stressful on the patients and their families but also not the most optimal therapy
and represents a huge financial burden on the Canadian health care system.

1.2.

Kidney injury Following Transplantation
There are generally two sources for organs for kidney transplants, namely

living donors and deceased donors. The latter can be divided into expanded criteria
donors (ECD) and standard criteria donors (SCD) depending on donor factors Which
alter long term survival in the recipient. ECD are classified by the Scientific Registry
of Transplant Recipients (SRTR) in the US by criteria of age and other conditions ie.
donors older than 60 years or donors older than 50 years with two of three
characteristics: 1) hypertension, 2) cerebrovascular cause of brain death, and 3)
pre-retrieval serum creatinine level greater than 1.5 mg/dL (130 pmol/1] [4, 5]. The
five year survival rate of a transplant patient is correlated with donor
characteristics with living donors being the greatest at 80%, followed by non-ECD
at 70% and ECD at 50% [6]. Even though living donors provide the greatest benefits
to patients, there is an insufficient number of donors to meet the needs of those in
the transplant waiting list, thus ECDs donors are used. In fact, the waiting list for
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kidney transplant continues to grow with the largest growth in the 50-64 years of
age group [6]. Approximately 6% of patients on the waiting list die while waiting
for a kidney transplant each year in the US in last decade [5].
Although short term graft survival rates has significantly improved over the
years due to anti-rejection drugs, long term graft survival has not changed [7].
Therefore, kidney transplants do not last indefinitely and graft survival appears to
be dependent on the health of the kidney pre- and post-transplantation. Patients
with failed kidney grafts are eligible to re-enter the waiting list for subsequent
transplants. Importantly, the survival time of each subsequent transplant decreases
markedly while survival on dialysis after transplantation is significantly worse. In
Canada, kidney graft failure is associated with a three-fold increase in mortality [8].
Therefore, there is a dire need to find new forms of therapies to prolong kidney graft
survival and thus minimize the need for multiple kidney transplants.
Transplantation is invariably associated with organ injury resulting from
ischemia-reperfusion injury (IRI) of the donor organ, inflammation, drug toxicity
and rejection. Tubular epithelial cell (TEC)s comprise of more than 75% of renal
parenchymal cells and their susceptibility to injury directs long-term function of
kidney allografts, as tubular injury can be a primary cause for nephron loss [9]. Post
transplant, TECs and other kidney cell death occurs with diverse etiologies and it is
increasingly apparent that kidney injury following transplantation is a continuous
process. IRI of the donor kidney remains as one of the earliest causes of injury and
has therefore been the target of many studies. Transplant injury can be divided into
several components.

1.2.1

Acute Ischemia Reperfusion Injury
IRI consists of ischemia followed by blood reperfusion, which activates

sequential and programmed inflammatory responses that result in cellular damage
and potentially irreversible loss of organ function. The ischemic stage begins with
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the cessation of oxygenated blood supply to the donor organ. In the absence of
oxygen, kidney cells are forced into anaerobic metabolism which results in the
gradual build up of toxic metabolites. Examples of toxic metabolites include free
radicals, hypoxanthine, lactate, nitric oxide and metabolic protons [10].

TECs

throughout the entire proximal tubule of the kidney are more metabolically active
than other epithelial cells [11, 12]. Thus, without blood supply, TECs are quickly
deprived of energy in the form of adenosine triphosphate (ATP) [12]. Without ATP,
energy dependent pumps such as Na+/K+ and Ca++ pumps in TEC basolateral
membranes are unable to maintain the solute gradients of Na+, K+ and Ca++ required
for proper function and survival [13, 14]. Malfunction of Na+/K+ pumps results in
the excess accumulation of Na+ inside the cell and ultimately the induction of cell
death due to the unregulated osmosis of water into the cell. In addition to the toxic
metabolites, cellular alterations causing the release of proapoptotic proteins from
mitochondria can induce programmed cell death or apoptosis [15].

1.2.ii

Recruitment o f Cells Via Chemotaxis Following Reperfusion
Reperfusion

following ischemia consists

of the re-establishment of

oxygenated blood flow to the transplanted kidney. During the reperfusion stage,
oxygenated blood returns to the graft carrying immune cells that are attracted to the
ischemic kidney. Cells under stress may secrete chemoattractants that can attract
inflammatory effector cells. As well, ischemia can prime cells for apoptosis, a form
of programmed cell death as well as necrosis, which release molecules that can
promote infiltration of pro-inflammatory cells. The oxygen in the fresh blood can
react with the accumulated toxic metabolites in the local milieu of the kidney
extracellular space to produce reactive oxygen species and further induce kidney
cell death. Influx of diverse cells such as neutrophils, cytotoxic CD8+ T cells, natural
killer [NK] cells, macrophages and monocytes can infiltrate the kidney and may
block local microvessels to promote ischemia. In addition, various inflammatory
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cells are capable of producing inflammatory cytokines and chemokines to further
perpetuate the inflammatory response by recruiting more inflammatory cells that
elicit more injury.
Cytokines are molecules that are used by inflammatory cells for intercellular
communication.

Cytokines can be classified as small peptides, proteins, or

glycoproteins and can induce a variety of immunomodulative properties such as
cellular proliferation, cell death, and induction of other cytokines.

Cytokines

commonly produced by effector cells during inflammation include: interferon
gamma (IFN-y), interleukin (IL)-2, macrophage chemotactic protein-1 (MCP-1),
interferon gamma-induced protein (IP-10), tumor necrosis factor alpha (TNF-a),
and IL-1. Furthermore, there are a sub-type of cytokines called chemokines.
Chemotaxis involves cells detecting specific chemotactic molecules in the
immediate fluid environment which directs cell movement towards those molecules
in a concentration dependent manner. The molecules that attract cells are
collectively termed chemoattractants. Cells that preferentially migrate towards a
chemoattractant of increasing concentrations must possess a receptor for that
molecule. It should be noted there are other forms of induced cellular locomotion
other than chemotaxis, such as chemokinesis, haplotaxis and necrotaxis. While
chemotaxis induces locomotion of cells towards a specific molecule in a
concentration

dependent manner,

chemokinesis induces increased random

movement of cells and is likely used as an environmental surveying function by
For example, during an inflammatory response, TNF-a is released and increases
random movement of IL-2 activated NK cells [16]. However, TNF-a can indirectly
stimulate chemotactic factor release such as IL-8 [17]. IL-8 has been shown to
induce T cell and neutrophil migration in a concentration dependent manner in a
fluid phase [18]. Haplotaxis is similar to chemotaxis in which it induces cellular
movement towards a concentration gradient; however, it differs from chemotaxis
due to the fact that these chemoattractants are surface associated whereas
chemotaxis occurs in a fluid filled environment. For example, the expression of
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laminin on the surface of nerve cells promote Schwann cell adhesion and migration
in a concentration dependant manner [19]. Necrotaxis is a subtype of chemotaxis
where the chemoattractants are released from apoptotic or necrotic cells.
Chemotactic cytokines or chemokines may function within a fluid
environment or bound to cell surfaces. Chemokines are promiscuous in that a single
chemokine can bind several different receptors or different allosteric sites of the
same receptor to confer different messages. Chemokine receptors belong to a large
family of 7-transmembrane G-protein coupled receptors [20].

There are

approximately 40 chemokines that have been classified into four families according
to unique cysteine configurations in their N-terminus: CC-, CXC-, C-, and CX3C(reviewed in [21]). Other than lymphocyte trafficking, chemokines contribute to
other biological functions including: angiogenesis, tumor metastasis, lymphoid
development, Thl/2

polarization and wound healing [21].

For example,

macrophage inflammatory protein-1-alpha (MIP-la) promotes T h l polarization,
while MCP-1 promotes Th2 polarization [22]. Overall, chemotactic agents have been
viewed for some time as potential therapeutic targets to control inflammation by
regulating differentiation and migration of immune cells [20, 23-25].

Indeed,

previous studies have shown that modification in the N-terminus of chemokines can
produce antagonistic properties. For example, regulation upon activation, normal
T-cell expressed, and secreted (RANTES) N-terminal modifications lead to inhibition
of CCR5 receptors and N-terminus truncation for MCP-1 can attenuate arthritis in
Fas deficient mice [26-28].
Various assays have been used to measure chemotaxis of prokaryotic and
eukaiyotic cells.

A common assay for measuring prokaryotic cell chemotaxis

employs semi-solid agar plates and spaced wells which are loaded with the
chemoattractant and cells of interest. Cells are then visually quantified as they
migrate towards the chemotactic agent which diffuses out of the initial loading site
in a decreasing concentration over distance gradient. Eukaryotic cell assays use a
similar concept using a fluid filled chamber system that was pioneered by Stephen
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Boyden [29], known as the Boyden chambers.

This system uses a fluid filled

chamber that is separated into two compartments by a membrane of a designated
pore size. Motile cells are placed in the upper chamber above the membrane, while
the chemotactic agent is loaded into the lower chamber at an appropriate
concentration. Chemotaxis requires cells to actively change their morphological
shape to migrate through the membrane towards the lower chamber.

Controls

include random migration without the addition of chemoattractant to the lower
chamber. The quantification of the chemotaxis assay can be done by counting cells
that have transmigrated into the lower chamber or to the lower side of the
membrane. Quantification methods include manual counting of migrated cells via
microscopy, various viability dyes, and flow cytometry.
During inflammation, chemokines can be secreted by non-immune cells such
as endothelial and epithelial cells [30, 31]. Chemokines have been implicated in the
recruitment of diverse inflammatory cells during IRI including NK cells which have
recently received greater attention for their role in inflammatory kidney injury. NK
cells are cytotoxic cells that are part of the innate immune system. NK cells serve as
a defence against cancer cells and viral infected cells. NK cells cytotoxic abilities are
regulated by inhibition and activation receptors.

An example of a surface NK

inhibition receptor is Ly-49s in mouse, and this receptor interacts with major
histocompatibility complex-1 (MHC-1) on target cells.

Therefore, cells without

MHC-1 will not inhibit NK's cytotoxic abilities by the NK inhibitory receptor, Ly-49
and will be killed via perforin and granzyme B [32]. NK cells also possess activating
receptors, an example, natural killer cell receptor-2 D (NKG2D). NKG2D interacts
with ligands such as retinoic acid early inducible-1 (Rae-1) and murine ULBP-like
transcript 1 [MULT-1] [33-35]. The panel of NK relevant chemokines in IRI and
kidney transplantation includes but is not limited to, MCP-1, IP-10, M IP-la, RANTES
and fractalkine (CX3CL1) [36-38]. The control of NK cell migration in response to
cytokines may be a key target in therapeutic strategies to limit inflammatory kidney
injury.
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1.2.iii Kidney Cell injury and Death
Kidney TECs and other parenchymal cells are injured in transplantation as a
result of IRI, toxic drugs and rejection.

Rejection injury occurs as a result of

cytotoxic effector cells as well as the various cytokines that they express.
Inflammatory cytokines within an inflammatory kidney environment can include
IFN-y, TNF-a and IL-2 which have been shown to mediate or promote apoptosis in
TECs via the activation of the caspase-8 pathway [39,40].
Kidney cells can also be injured or killed by direct ligation with cytotoxic cells
such as CD8+ T cells and NK cells [34, 41, 42]. These cytotoxic effector cells induce
apoptosis

via

Fas-Fas

ligand

interaction

or

by

perforin/granzyme B (Prf/GrB] pathway [34, 43, 44].

the

activation

of the

B cells contribute to the

injury of allografts via antibody mediated rejection in conjunction with complement
proteins [45].
During kidney injury, whether due to IRI or rejection, individual kidney cells
undergo cell death as a result of two primary pathways, namely apoptosis and
necrosis. While apoptosis and necrosis have distinct characteristics, they also share
similar etiologies, and a balance between apoptosis and necrosis is required to
maintain the homeostasis of an organism [46].

Apoptosis is characterized by

rounding-up of the cell, reduction of cellular volume (pyknosis), chromatin
condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing,
and phosphatidylserine [PS] exposure on the cell surface. PS normally resides in the
inner leaflet of the plasma membrane. During early apoptosis, PS translocates onto
the outer cell surface and in turn confers positive phagocytosis "eat me" signals to
neighboring phagocytic cells [47]. The apoptotic process is efficient and usually
induces minimal inflammation in the kidney, since TECs express the PS receptor,
kidney injury molecule-1 (KIM-1), which may permit TECs to remove apoptotic cells
[48]. Apoptosis of TECs within the kidney may be inconspicuous due to the short
half-life of apoptotic cells [46]. Clearly the rapid removal of apoptotic cells is
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important to immune homeostasis as autoimmune inflammatory diseases can arise
if phagocytosis of apoptotic cells is inhibited [49, 50]. TECs also express various
surface adhesion molecules which can promote injury. TECs can upregulate the
expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM1] and, intercellular adhesion molecule-1 (ICAM-1) by inflammatory cytokines such
as TNF-a [51, 52]. These adhesion molecules on kidney cell surfaces can promote
interactions with effector cells such as cytotoxic CD8+ T and NK cells.
Apoptosis can be receptor independent or dependent. Death receptors (DR)
belong to the tumor necrosis factor receptor (TNFR) superfamily and includes TNFR l, CD95 (Fas) and several members o f the tumor necrosis factor-related apoptosisinducing ligand

[TRAIL] family [53, 54]. Apoptosis requires the activation of a

cascade of caspases that consists of intracellular cysteine proteases [53].

The

activation of caspases that promote the apoptosis pathway involves the binding of
ligands to DR which promotes receptor oligomerization (trimerization).

The

oligomerization of receptors results in the cytoplasmic recruitment of several
adaptor proteins including members of the receptor interacting protein [RIP] family
and pro-caspase 8 to form the death-inducing signaling complex [DISC] [51, 55]. In
the DISC, processing of pro-caspase 8 leads to downstream activation of caspase 3,
and 7, ultimately cleaving nuclear lamins [56], DNA repair enzymes[57],
cytoskeleton proteins such as actin [58] and inhibitor of caspase activated DNase
[iCAD].

The cleavage of iCAD results in the commencement of the DNA

fragmentation process[59]. Apoptosis can also occur after mitochondrial proteins
such as cytochrome c and Second mitochondrial derived activator of caspases
[Smac/Diablo] are released into the cytosol to activate caspase-9 and then caspase8. Smac/Diablo are found in relatively high abundance in kidney tubules and their
induction is increased by TNF-a induced apoptosis [60, 61].

Smac/Diablo induces

the auto-degradation of cellular inhibitors of apoptosis proteins (cIAP) 1 and cIAP2
to promote the formation of RIPl-containing caspase-8 activating complexes [61].
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Caspase-8 can cleave the Bcell lymphoma 2 (Bcl-2) family member Bcl-2 intervaling
domain (Bid], to promote the mitochondrial pathways of apoptosis[46].
Apoptosis regulation within TECs is important to inflammation control, since
excessive inflammation can lead to kidney dysfunction. Kidney TECs have been
known to self regulate apoptosis by the expression of the endogenous caspase-8
inhibitor c-FLIP (cellular Flice-inhibitory protein] which can inhibit Fas and TNF-R1
mediated apoptosis [39, 62, 63]. Inhibitor of apoptosis proteins (IAPs] is another
example of endogenous regulators that can inhibit caspase activation ([64], and
reviewed in [65, 66]]. Although the loss of donor kidney expression of FasL or Fas
may provide an advantage in transplants due to reduced TEC fratricide or
susceptibility to cytotoxic cell induced injury [40, 67], the loss of kidney Fas does
not exclude caspase-8 induced apoptosis by other receptor pathways ie TRAIL. TECs
also express SPI-6 (Serpin protease inhibitor-6] which is a specific inhibitor of GrB
mediated apoptosis.
In contrast to apoptosis, ‘necrosis' is morphologically characterized by a gain
in cell volume (oncosis), loss of plasma membrane integrity and release of
intracellular contents such as danger associated molecular patterns molecules
(DAMPs) that may perpetuate immune responses. Different forms of necrosis (ie.
pyroptosis, necroptosis and secondary necrosis) may play a role in various forms of
inflammatory kidney injury. Inflammasome-dependent caspase-1 activity results in
necrotic cell death known as pyroptosis

[68-70] and has been recently

demonstrated to play a role in obstructive ureteric kidney injury [69]. Necrosis can
be induced in many ways, and some examples include TNF-induced necroptosis,
H2Û 2-induced necrosis and anti-Fas-induced secondary necrosis. Although there are
different ways to induce necrosis, they often share common cellular events such as
oxidative burst, mitochondrial membrane hyperpolarization, lysosomal membrane
permeabilization and plasma membrane permeabilization [70]. Furthermore, due
to commonalities of the necrosis pathways, one form of necrosis can elicit other
forms as well. Necrosis, like apoptosis, can also be regulated by signal transduction
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pathways. Regulated necrosis may exist as a mechanism to promote inflammation
and kill virus-infected cells if apoptotic pathways are subverted [66, 71]. This
regulated form of caspase dependent necrosis has been recently been termed
'necroptosis' [72, 73]. This form of cell death may be promoted if apoptosis is
blocked and ultimately leads to a greater inflammatory response through the
release of DAMP molecules such as high mobility group protein-1 [HMGB1] and heat
shock proteins [HSP] [74-76].

In the presence of inflammation, cell death is

unavoidable. Both apoptosis and various forms of necrosis are difficult to avoid after
kidney transplantation. However, without control of excessive cell injury or death,
organ dysfunction or failure is inevitable.

1.2.ÎV Transplant Rejection
There are three general forms of allograft rejection: hyperacute, acute, and
chronic. Hyperacute rejection is a combination of complement and pre-existing
antibodies which can cause immediate and severe injury. This response can be
observed within minutes after transplantation and the graft must be promptly
removed to prevent further severe systemic inflammation.

Acute rejection can

begin within days or weeks of transplantation. While the greatest risk for acute
rejection is within the first three months after transplantation, the process may
occur anytime after transplantation. This process begins with naive T cells that
require approximately 7 days for complete differentiation and maturation into
effector cells following antigen exposure from the donor graft.

Finally, chronic

rejection refers to rejection injury over long periods of time with gradual loss of
function of the graft. Alloantibody may participate in chronic injury. Usually the
chronic loss of function in kidney grafts is associated with histological
demonstration of tubular atrophy and interstitial fibrosis. However, non immune
mechanisms of injury including recurrence of the original disease, viral infection
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(BK Virus), and drug toxicity may be indistinguishable from immune rejection
mechanisms.
As previously mentioned, T cells are involved in acute rejection, and are
primed for an adaptive immune response at the onset of IRI. Injury sustained by the
kidney in the IRI phase results in the upregulation of several factors that increase
the risk of kidney rejection including major histocompatibility complex (MHC)
antigens, chemokines, proinflammatory cytokines, adhesion

molecules, and

activation of innate immunity via DAMP release [74, 77, 78].

Alloantigen

recognition by T cells begins with antigen presenting cells (APCs) such as donor or
recipient dendritic cells (DCs).

Circulating recipient immature DCs and

macrophages may acquire donor antigens after infiltrating the donor kidney and
present alloantigens to T cells and activate them in peripheral lymphoid organs[79].
Furthermore, kidney endothelial and TECs can express MHC class II molecules to
potentially present alloantigens to T cells, and thus contribute to the rejection
process [80, 81].
Recipient T cells can be activated through donor or recipient DCs that carry
alloantigens from the donor kidney. In addition to the alloantigen presentation by
MHC molecules on DCs to the T cell receptors on T cells, a secondary activation
signal is also necessary. The second signal involves costimulatory molecule CD28 on
T cells to recognize and bind to B7 protein (CD80 and CD86) on the APC. The
activation of adaptive immunity by these pathways leads to the expression of
inflammatory cytokines such as IL-2 that binds to IL-2 receptor on CD4+ T helper
and CD8+ cytotoxic T cells which results in their activation and proliferation. There
are three types of CD4+ T helper (Th) cells, T h l, Th2, and T hl7. T h l predominantly
governs cell mediated rejection along with the CD8+ effector T cells and promotes
inflammatory cytokine production. In contrast, the Th2 pathway promotes antibody
production and suppresses the inflammatory T h l pathway.
associated

with

encephalomyelitis

autoimmune

diseases

such

as

T h l7 cells are

experimental

autoimmune

(EAE) [82]and inflammatory bowel disease[83].

In a T h l
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deficient mouse cardiac transplant model, there is evidence of improved allograft
survival when IL-17 or T h l7 inducing cytokine IL-6 is neutralized [84, 85].
However, currently there is no definitive data indicating Thl7's direct role in
regulating allograft rejection [86]. The lack of direct relation between T h l7 and
allograft rejection is because the major method of detection of Thl7 has largely
been dependent on the hallmark production of IL-17 cytokine, however, IL-17 is
also produced by CD8+ T cells, NK T cells, and macrophages [87, 88].
The development of T cell subtypes is regulated by cytokine expression. Th l
inducing cytokines typically are IFN-y and IL-2. In contrast, IL-4 polarizes Th cells
towards Th2 differentiation. T h l promoting cytokines promote the function and
differentiation of T h l cells while preventing Th2 cell differentiation. Similarly, Th2
cytokines promote Th2 responses while inhibiting T h l cell differentiation. Finally,
T h l7 inducing cytokines include transforming growth factor-beta [TGF-(3], IL-6, IL21, and IL-23.

Cytokines that are produced by Thl7 cells are predominantly

comprised of IL-17, IL-21, and IL-22 [86].

Altogether, the balance of cytokines

present in a transplant graft will regulate the differentiation of Th cells and
recruitment of inflammatory cells which dictate the degree of inflammation and
damage in the allograft.
The activation of naive T cells as well as regulation of effector T cells is
controlled by a regulatory subtype of T cells, known as CD4+CD25+ FoxP3+ T
regulatory [Treg] cells which have been most extensively characterized in mouse.
While the mechanism(s) of these Tregs have not been completely elucidated, their
ability to 'regulate' T cells appears to be dependent on the expression of surface
receptors [CTLA-4] and the elaboration of cytokines such as IL-10 and TGF-p [89,
90]. In animal models of transplantation, Tregs have been shown to contribute to
graft tolerance. However, the role for CD4+CD25+ FoxP3+ Treg in human allografts is
less clear as some studies suggest this phenotype is also present in effector T cell
activation and the severity of rejection is correlated directly rather than inversely
with Tregs [91-94], Although Tregs are widely accepted to regulate components of
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the adaptive immune system, there is evidence that these cells also participate in
innate immunity. In a fully allogenic mismatched bone marrow transplant mouse
model, depletion of CD25+ cells by monoclonal antibody resulted in a marked
increase in rejection of the donor bone marrow by host NK cells [94].
mediated graft rejection can be regulated by Treg cells via TGF-(3.

NK cell

TGF-p can

suppress NK cells in vitro and administration of anti-TGF-p monoclonal antibodies
resulted in accelerated graft rejection. Thus, Tregs may play an important role in
protecting allografts against NK mediated cytotoxic effects [94,95].
Chronic inflammation can lead to fibrosis and graft failure.

Continuous

expression of cytokines (IL-1, IL-12, IL-18, IFN-y, TNF-a] from activated
inflammatory cells such as macrophages can lead to the impairment of graft
function and gradual loss of cells due to apoptosis [96]. Fibrosis disrupts the highly
organized architecture within the kidney and results in the reduced filtration
efficiency as well as loss of cells that perform other functions. Fibrosis can be
promoted by pro-fibrotic cytokines produced by the kidney itself (TGF-ip) as well
as inflammatory infiltrates such as macrophages, B cells and T helper cells. TGF-ip
remains the most potent kidney pro-fibrotic cytokine and is activated by cleavage of
pro-TGF-pi by matrix metalloproteinase-9 (MMP-9) and CD44 associated with cell
surfaces [97-100]. Collectively, chronic inflammation by diverse causes can reduce
the number of functional kidney cells and the progressive accumulation of
interstitial fibrosis will lead to the loss of function in the kidney.
Kidney transplantation remains the treatment of choice for long term kidney
failure, but is limited by the number of donors and the longevity of the graft.
Without doubt, advances in immunosuppression have improved short term allograft
survival. However, long term survival rates beyond five years have not significantly
changed in the last 3 decades [7]. While many potential explanations exist, it may be
that the exclusive use of drugs that mainly focus on adaptive immunity including
CD4+ and CD8+ T cells without targeting innate immunity: a major pathway of long
term injury. Currently there are no drugs that effectively provide any long term
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control of inflammation, or promote regeneration and repair. OPN was chosen as a
target in this study for its potential for therapeutic interventions in transplantation,
given its potent and diverse effects on chemotaxis, cell survival and inflammation.

1.3.

Osteopontin - Structure and Characteristics
OPN is a negatively charged phosphoprotein. It consists of 300 amino acids

with an apparent nascent weight of 33kDa. It can be extensively post-translationally
modified to 44kDa by methods of glycoslyation, phosphorylation and sulfation [101,
102].

OPN contains an arginine-glycine-aspartic acid (RGD) motif [103] that is

highly conserved across many species [104]. OPN has chemokine, cell adhesion and
cytokine properties which appear to operate through this RGD domain. The RGD
domain has been shown to facilitate chemotaxis and cell adhesion via binding to
av(33 integrin receptors or CD44 on various types of cells [105-108]. OPN contains a
thrombin cleavage site directly downstream of the RGD domain. OPN fragments
that are generated by thrombin cleavage have been identified as factors that
increase a cell's adhesive characteristics more so than the native OPN protein [109,
110]. OPN has also been shown to be a substrate of MMP, such as MMP 3, 7, and 9
[111, 112]. Cytokine properties are also present as OPN can stimulate c-src, and
phosphoinositide 3-kinase/akt pathways in a variety of cells [105, 113-115]. OPN
protein has three isoforms: soluble forms that are associated with chemotaxis and
cell adhesion, and an intracellular form whose function is not yet clearly known
[102]. OPN is widely expressed in many cell types of both immune and non-immune
cells. It is also known to be expressed in TECs, but its function in TECs during kidney
injury has yet to be determined [102,116-119].
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1.3.i

Osteopontin Functions
OPN is a multi-functional protein that can influence chemotaxis in immune

cells, cell survival, inflammation, cell adhesion and development depending on the
type of post-translation modifications [102, 105, 119-123]. Furthermore, it was
shown that OPN synthesis and isoforms in ischemic rat kidneys were similar to
those found in ischemic human kidneys [119], This supports the relevance of rodent
animal models for OPN studies in IRI and human transplantation related injury. OPN
was identified as a chemotactic agent for a variety of cells such as osteoclasts,
smooth muscle cells, macrophages and monocytes [124-126]. Our research group
and others have shown that in rodent IRI models, OPN'/- kidneys have decreased
macrophage and natural killer cell infiltrate populations within 24 hours post IRI
[118, 120, 126, 127]. Furthermore, it has been shown that NK cells contribute to
kidney injury in the early phases of IRI after kidney transplantation [34,118]. It has
also been shown that long term cardiac graft acceptance cannot be maintained in
the presence of T cell tolerance without the co-depletion of NK cells, suggesting NK
cells play an integral role in the indefinite acceptance of allografts [128].

Despite

the importance of NK cells in IRI and long term graft survival, it has not yet been
demonstrated if TECs express OPN in response to inflammatory stress or whether
OPN is indeed a chemotactic agent for NK cells.

It is possible that if NK cell

mediated damage to TECs in the kidney can be reduced, OPN may be the key to
indefinite allograft acceptance.
OPN has been described as a pro-survival factor for many cell types including
cancer cells, endothelial cells, T cells, dendritic, monocytes and macrophages [121,
123,129-132]. This property of OPN has been demonstrated through the use of OPN
ligation with CD44 cells in vitro in murine proB cell lines [115]. More specifically,
interactions of OPN with CD44 receptors lead to phosphoinositide 3-kinase [PI3k]
and Akt signalling and results in the cessation of programmed cell death.
Furthermore, according to Lin et al., the presence of threonine 137 and serine 147
residues are critical to facilitating these pro-survival effects induced by OPN. While
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there are several known variants of CD44, the variants which do show antiapoptotic properties upon interaction with OPN are the variants v6 and v7 [133].
Other cells which similarly demonstrated anti-apoptotic properties upon interaction
with OPN are T cells. T cell survival was promoted by OPN through the activation of
NFkB and inhibition of the pro-apoptosis transcription factor, Foxo3a in T cells
a substrate of the Akt pathway involved in DNA repair and apoptosis. Furthermore,
OPN has also been demonstrated to contribute to T cell survival by inhibiting
nuclear translocation of apoptosis inducing factor (AIF) by Hur et al [129].
Interestingly, neutralizing OPN with anti-OPN antibody can increase apoptosis in
activated T cells. T cell apoptosis appeared to be related to NFkB inhibition, an
increase in pro-apoptotic proteins, Bim and Bax and a reduction of the anti
apoptosis protein, Bcl-2 [132]. These results would suggest that while OPN may
promote IRI through mechanisms such as NK attraction, a benefit from OPN during
chronic inflammation may not be predictable as loss of OPN may result in altered
parenchymal cell survival or alterations in T cell effector and regulatory subsets.
In addition to OPN’s pro-survival effects, OPN also possess pro-inflammatory
cytokine properties [105]. OPN has been classified as a T h l cytokine for its ability
to promote T h l related cytokine production in macrophages and T cells. OPN is a
major product of differentiated macrophages [134] which also promotes the
expression of other inflammatory cytokines including TNF-a, IL-1(3, IFN-y, and IL-6
[135-137], In mouse kidney epithelial cells, OPN can inhibit the expression of nitric
oxide synthase, a potent mediator of TEC injury during hypoxia and re-oxygenation
[10, 137, 138]. OPN can contribute to the retention and survival of macrophages,
and thus contribute to chronic injury.

Similarly, activated T cells produce OPN.

Expression of OPN is dependent on the transcription factor T-bet [139] and T cell
differentiation towards the T h l pathway is impaired in OPN'/- mice. It follows that
OPN-/- mice have impaired ability to resist infections from intracellular pathogens
such as Listeria monocytogenes and Herpes simplex virus type 1 [140].

OPN-/- mice

also have reduced IFN-y and IL-12 production, but have enhanced IL-10 expression
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[137]. Taken together, OPN is not only a chemoattractant for inflammatory cells,
but also drives inflammation at the site of injury by promoting differentiation of
effector cells and the secretion of inflammatory cytokines.

1.3.ii

Osteopontin Expression
OPN expression can be induced by cytokines, inflammation, surgical injury,

and cellular development. OPN expression is ubiquitous as it can be produced by
most cell types including activated T cells, macrophages, dendritic cells and
endothelial cells [102,104,123,141,142]. However, the highest levels of expression
have been found in bone and epithelial cell rich tissues [104]. TECs represents the
largest component of parenchymal cells in the kidney, therefore, expression of OPN
would be expected. Indeed, OPN is constitutively expressed in the kidney, most
strongly in the proximal tubules upon injury [117, 143]. OPN can be induced by
TGF-P via the Smad (please see abbreviations list) signaling pathway using the hox
binding element in the OPN promoter [144]. Both TGF-(3 and epidermal growth
factor (EGF) induce OPN in cultured rat renal epithelial cells [145]. Furthermore,
the inflammatory cytokine, TNF-a stimulates OPN production in human bile duct
epithelial cell cultures [146, 147].

Therefore, it may be possible that OPN

production by TECs may be responsive to inflammatory cytokines such as TNF-a.
Kidney expression of OPN has been demonstrated in several kidney injury models
including unilateral ureter obstruction (UUO), ischemia and IRI [117-119, 122, 143,
148,149].
1.4.

Background on OPN-/- Mouse
Genetically altered and gene null mice incapable of expressing specific

proteins are powerful reagents for studying the role of cytokines in inflammatory
injury and transplant rejection. In this study we utilized an OPN'/' mouse that had
been generated by Kittling et al [150]. OPN-/- mice appear to be phenotypically
normal and are fertile, however, it should be noted that they have an impaired T h l
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response against intracellular pathogens.

In addition, there is an increased

frequency in osteoclast generation in vitro using cells obtained from OPN-/- mouse’s
spleen and bone marrow, suggesting an important regulatory role for OPN in bone.
Site directed mutagenesis in the OPN gene was used to disrupt the integrin binding
site and produce a truncated version of the wild type protein [150]. The approach
used a 4.8kb genomic OPN sequence from the 129Sv mouse strain and targeted the
immediate 5’ region of the RGD sequence. The result of the gene disruption is a
partial OPN sequence without the critical RGD sequence required to bind to integrin
receptors such as CD44 and integrin av(33. C57BL/6(B6] x 129Sv OPN-/- mice were
backcrossed to B6 for nine generations. It should be noted that some truncated Nterminus OPN fragments can be detected at levels 100-200 fold lower than in wild
type OPN mice, but functions, if any, of truncated forms are unknown [150].

1.5

Rationale and Hypothesis
In summary, OPN is a potent, multi-functional cytokine that can influence cell

development, survival, as well as inflammation. While OPN is primarily produced in
the kidney, and is increased with the event of injury, its function in TECs during
kidney injury has not been clearly defined.
These studies were undertaken to test the hypothesis that kidney TEC
expression of OPN regulates hypoxic and inflammatory kidney cell injury through
interactions with NK cells and its anti-apoptosis effects on TECs. Finally, the role of
OPN in kidney transplantation has not been previously tested. We utilized kidneys
from B6 OPN-/- mice for fully MHC mismatched (B6, H-2b -> Balb/c, H-2d)
transplants, to test for graft survival, function and histological kidney injury in the
absence of OPN. Collectively, our results combined with other studies support an
important but complex role of OPN in kidney inflammatory injury. Results from the
current study are important in future consideration for therapeutic strategies in
renal transplantation that involve manipulation of OPN.
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2. Materials and Methods
2.1.

Mice
C57BL/6 (B6) and Balb/c mice (males, 6-8 weeks old) were purchased from

Jackson Laboratories (Bar Harbor, ME, USA). The OPN'/' mice were developed in
129Sv mice and backcrossed into B6 mice for 9 generations [150]. All mice used in
this study were maintained in the animal facility at the University of Western
Ontario. Animal experiments were conducted in accordance with the Canadian
Council of Animal Care guidelines with protocols approved by the Animal Use
Subcommittee of the University of Western Ontario.

2.2.

Antibodies and Reagents
All antibodies were produced in goat and targeted against mouse unless

specified.

TECs were characterized with the following fluorescent staining

antibodies: anti-CD13-PE, anti-CD26-PE and anti-E-cadherin-FITC (eBiosciences,
San Diego, CA). Anti-OPN (polyclonal) and recombinant mouse OPN (rmOPN) were
purchased from R&D systems (Minneapolis, MN, USA).

Cell viability assays

identifying necrotic and apoptotic cells employed propidium iodide (PI) and
Annexin V (AV).

PI and AV were purchased from eBiosciences. Cells stained with

fluorescent antibodies or dyes were analyzed with a Cytomics FC500 flow cytometer
(Beckman Coulter, Mississauga, ON, Canada).

The following antibodies were

ordered from Cedarlane (Burlington, ON, Canada): biotin anti-mouse CD4, biotin
anti-mouse CD8, biotin anti-mouse Mac-1, B220: purified rat anti-mouse CD45RB
(B220). Mouse cytokines IL-2, TNF-a, and IFN-y were purchased from PeproTech
(Rocky Hill, NJ, USA).
Cultures of TECs were maintained in complete K1 media ((DMEM:HamsF12,
50:50, (Invitrogen-Life Technologies, Carlsbad, CA), supplemented with 5% bovine
calf serum,

hormone

mix

(5pg/ml

insulin,

1.25ng/ml

PGE1,

34

pg/ml
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triodothyronine, 5pg/ml transferrin, 1.73 ng/ml sodium selenite, and 18 ng/ml
hydrocortisone], 100 U/ml penicillin (Invitrogen), 100 ng/ml streptomycin
(Invitrogen), and 25ng/ml epidermal growth factor (EGF) (Sigma-Aldrich, St. Louis,
MO)].

Incomplete K1 media consisted of only DMEM and HamsF12 at equal

proportions.

2.3.

Primary Kidney Cell Isolation and Culture
Primary kidney cell cultures were obtained from the cortex region of either

B6 OPN+/+ or B6 OPN'/- mouse kidneys after digestion with collagenase at lmg/ml
(Sigma) for 15min in complete K1 media in a humidified incubator at 37°C. The
digested cells were then passed through a 40pm cell strainer (BD Biosciences, San
Jose, CA) and washed with 20ml of PBS. The single cell suspension was then grown
in complete K1 media in a 75 cm2 vented flask (BD Bioscience, San Jose, CA) in a
humidified incubator at 37°C. Trypsin-EDTA at 0.125% was used for each passage
cycle with prior washing using PBS without Mg2+ and Caz+(Invitrogen). Tubular
epithelial cell phenotype (monolayer cobblestone pattern) was confirmed by
microscopy as well as flow cytometry using fluorescent antibodies: anti-CD13-PE,
anti-CD26-PE, and anti-E-cadherin-FITC (eBiosciences) (data not shown).

2.4.

In Vitro OPN Stimulation Assay o f TECs
Primary B6 TECs were plated at 2x10s and were cultured to near confluence

in K1 complete media. The cells were gently washed with PBS prior to treatments.
The treatment groups consisted of TECs bathed in K1 incomplete media with: no
treatment, addition of 5% FBS and 0.05 ng/ml EGF, increasing concentrations of IL2 (1.0, 5.0, 25.0 ng/ml), increasing concentrations of TNF-cx (5.0, 10.0, 20.0, 40.0
ng/ml), and increasing concentrations of IFN-y (5.0, 10.0, 20.0, 40.0 ng/ml). The

22

final volume of each well in the 24 well plate was 400pl. Supernatant was collected
24 hours later and stored in -80°C until analysis for soluble OPN.

2.5.

Isolation o f NK Cells
NK cells were purified from B6 mouse spleens by gently passing the spleen

through a 40pm cell strainer (BD Biosciences, San Jose, CA), washed with 10ml PBS
and spun down at 1000 x g (gravity) for 5 minutes. The pellet was subsequently
resuspended in 1ml of ACK lysis buffer (Invitrogen GIBCO, Burlington, ON) for 30
seconds and washed with 10ml of PBS. Subsequent isolation was performed as
described in MACs cell separation kit (Miltenyi Biotec, Auburn, CA). Briefly, a single
cell suspension was made in 490pl of MACs buffer (PBS, 1% FBS, 0.5% EDTA) and
incubated with 10pl of magnetic beads conjugated anti-CD3 (Miltenyi Biotec,
Auburn, CA) for 15 minutes at 4°C. Cells were then washed with 9.5ml of MACs
buffer and centrifuged for 5 minutes again. Washed cells were then resuspended
well in 500pl of MACs buffer and transferred into a MACs midsize column (Miltenyi)
that was subjected to a magnetic field.

The column was washed three times with

500pl of MACs buffer and the flow through was collected and spun down. Cells were
resuspended and incubated with lOpl of magnetic beads conjugated to anti-CD49b
(Miltenyi) for 15 minutes at 4°C. Cells were washed again with 10ml of MACs buffer
and subsequently resuspended in 500pl of MACs buffer. The cell suspension was
then loaded into the midsize column (Miltenyi) and subjected to a magnetic field
and washed three times with 500pl of MACs buffer. After the third wash, 500pl of
complete RPMI media (10% FBS) was loaded onto the column and pushed into a
new sterile tube manually by a plunger provided by the kit (Miltenyi). Cells were
washed with 9.5ml of PBS and were ready to be used. Purity of NK cells were
confirmed by flow cytometry analysis and was found to be >94% CD3'CD49b+.
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2.6.

Chemotaxis Assays
NK cell chemotaxis towards TECs first required plating of TECs (2x10s) in

24-well plates overnight with or without treatments of increasing concentrations
(0-5pg/ml) of rmOPN (R&D Systems) in K1 incomplete media. Purified NK cells
were

labeled

with

0.5-0.8pM

of CFDA-se

(carboxyfluoresceindiacetate

succinimidyl ester) (Invitrogen) for 8 minutes in RPM1 media.

N-

Cells were then

washed with complete K1 media and loaded (10s) on the upper chamber of the
transwell (Costar, Cambridge, MA).

To maintain even hydrostatic pressures

between chambers, it was critical for the upper and lower chambers to have a final
volume of lOOpl and 600pl respectively. For treatments that included goat anti
mouse OPN antibody, the neutralizing antibody (5pg/ml) was added to the TECs in
the lower chamber one hour prior to the chemotaxis assay to allow for OPN
neutralization. After two hours of chemotaxis, cells in the lower chamber were
collected for analysis of CFDA-se positive cells (flow channel 1) by flow cytometry
using Cytomics FC500 (Beckman Coulter). Migration index was used to determine
efficiency of the NK cell migration.
A direct NK cell chemotaxis assay was performed in a similar manner
without TECs in the lower chamber. Furthermore, NK cells were not labeled with
CFDA-se.

Complete RPMI media was used and was supplemented with increasing

concentrations (0-2.5pg/ml) of rmOPN in the lower chamber. The NK cells in the
lower chamber were quantified by flow cytometry after two hours of chemotaxis. A
migration index system was used to evaluate NK cell chemotaxis. The migration
index (MI) was calculated by dividing the number of cells migrated into the lower
chamber due to a chemoattractant by the number of cells migrated in the absence of
a chemotactic agent. MI = (number of NK cells migrated with chemoattractant /
number of NK cells migrated without chemoattractant (media control)).
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2.7.

Mouse Kidney Reperfusion Injury induction
Surgeries were performed by a micro-surgeon (Dr. Shuang Wang) as

described in Zhang et al [118]. Briefly, kidney ischemia was induced in the mouse
by clamping the left kidney artery and vein for 45 minutes on a thermo-regulated
heating pad set at 32°C. The right kidney was removed after the clamp was released
on the left kidney vessels. At various time points, the mouse was sacrificed and
blood was collected from the inferior vena cava using a 32 gauge needle. Sham
controls were treated with the same operative procedures as the injury group
without clamping the left kidney.

2.8.

Serum Collection and Analysis
Serum was separated from blood that was collected from IRI subjected mice

by allowing the blood to clot in an eppendorf tube for 30 minutes at room
temperature and overnight incubation at 4°C. The blood sample was then further
separated by centrifugation at 2 000 x g at 4°C for 10 minutes. Serum creatinine
was measured using the standard Modified Jaffe reaction method by an automated
CX5 clinical analyzer (Beckman, Fullerton, CA). Urea was measured by the Roche
Modular P platform using the standard Roche ultra violet kinetic methodology
(Roche Diagnostics, Indianapolis, IN).

Creatinine and urea measurements were

performed using the MDS Laboratory Services (London, Ontario, Canada). Serum
was also analyzed for OPN with R&D Systems mouse OPN DuoSet enzyme linked
immunosorbant assay (ELISA) kit (R&D Systems, Minneapolis, MN). Soluble OPN
proteins measured from supernatants collected from in vitro TEC cultures were also
measured with the same ELISA kit.
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2.9.

Quantitative Polymerase Chain Reaction
Total RNA was extracted from cultured TECs from OPN+/+ and OPN'/' mice as

per described by manufacturer’s protocol (QIAGEN, Mississauga, ON). First Strand
Synthesis System kit was then used to convert lp g of RNA to cDNA as described by
the manufacturer's protocol (Stratagene, La Jolla, CA). The following primers were
used to screen for chemokine transcripts via quantitative polymerase chain reaction
(qPCR).

5'AGCACCAGCCAACT CTCACT'3

MCP-1:

5'CGTTAACTGCATCTGGCTGA’3.

M IP-la:

and

5'CCTCTGTCACCTGCTCAACA’3 and

5’GATGAATTGGGGTGGAATCT'3. RANTES: 5’ATATGGCTCGGACACCACTC’3 and
5’TCCTTCGAGTGACAAACACG'3.

IP-10:

5'GGATGGCTGTCCTAGCTCTG’3 and

5’ATAACCCCTTGGGAAGATGG'3. CX3CL1: 5’CCAAGAGCCCTGTGACATTT'3 and
5’CCTCACTCTCAGGAGCCAAC’3.

MK:

5'ACCGAGGCTTCTTCCTTCTC'3

5'GGCTCCAAATTCCTTCTTCC’3.

KC:

5’AGACTGCTCTGATGGCACCT’3 and

5’TGCACTTCTTTTCGCACAAC'3.

and

ß-Actin: 5'CCAGCCTTCCTTCCTGGGTA’3 and

5'CTAGAAGCATTTGCGGTGCA’3. The gene sequences were obtained from the
www.ncbi.nlm.nih.gov database.

Primers were designed with primer designing

software, Oligo Perfect Designer (Invitrogen). Each primer was checked to amplify a
single amplicon by PCR and thermal dissociation curves.

Quantitative PCR was

performed on standardized quantities of cDNA using the Brilliant SYBR Green qPCR
Master Mix kit (Stratagene). Amplified DNA products were generated and detected
using the Mx4000 system (Stratagene). Each PCR sample was setup in triplicate, pactin was used as an internal RNA reference control. The normalized delta threshold
cycle value and relative expression levels were calculated using the delta delta cycle
threshold method (2_ldeltaHdeltalct), where:
[delta] [delta] Ct —[delta] Ct,sample ” [delta] Ct,reference
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2.10.

In Vitro TEC Survival Assay
Primary TECs were isolated from a kidney of a naïve OPN+/+ or OPNK- mouse

and were cultured to 70-80% confluence in complete K1 media. TECs were serum
starved for 24 hours using K1 incomplete media. Treatment groups consisted of
TECs in incomplete K1 media with: no treatment, hypoxia, hypoxia with TNF-a and
IFN-y, and hypoxia with TNF-a, IFN-y and rmOPN. Note: Treatments that included
rmOPN (2pg/ml) treatment, were administered to the TECs 24 hours prior to
hypoxia and cytokine treatments.
TECs were serum starved for 24 hours in incomplete K1 media.

After 24

hours of serum starvation, fresh incomplete K1 media was prepared for
deoxygenation, by bubbling the media with nitrogen gas for 15 minutes.

The

deoxygenated K1 incomplete media was confirmed to contain less than 5% oxygen
using an oxygen optical sensor (Ocean Optics, FL, USA). The prepared deoxygenated
incomplete K1 media was then used to replace the serum starvation media. TECs
were

subsequently

treated

with

TNF-a

(20ng/ml)

and

IFN-y

(20ng/ml)

(PeproTech) and placed in a hypoxia chamber filled with nitrogen gas for 20
minutes at 32°C. TECs were cultured for 24 hours under normal culture conditions
and were subsequently quantified for cell death. Cell death was quantified 24 hours
later by flow cytometry on a Cytomics FC 500 flow cytometer (Beckman Coulter)
using PI and AV staining (eBiosciences).

2.11.

Kidney Transplantation
Ten week old male Balb/c mice were bilaterally nephrectomized and

transplanted with a single kidney from a male B6 mouse of similar weight as
described by Du et al [40]. Both donor and recipient mice were anaesthetized with
isoflurane. Donor kidney, ureter, bladder, renal artery and vein were recovered
together. Vascular vessels of the donor kidney were anastomosed to the recipient’s
respective abdominal aorta and inferior vena cava below the native renal vessels of
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the recipient.

Renal ischemia time was limited to 30-45 minutes.

Donor and

recipient bladders were attached dome to dome. Kidney graft survival was assessed
daily based on the overall health of the animal. If the recipient mouse was found to
be suffering, the mouse was sacrificed and tissues such as blood and kidney graft
were removed for analysis. The mouse was deemed suffering (in clinical distress)
and required to be euthanized when two or more of the following criteria have been
met: fur coat exhibited piloerection, lack of spontaneous withdrawal from stimulus,
prolonged closed or abnormal eye activity, lack of mobility, abnormal posture
(hunched back, non-functional hind limbs) and continuous weight loss 3 days post
transplantation. Mice were followed up to 100 days and were subsequently
sacrificed.

2.12.

Kidney Graft Function and Injury Assessment
Kidney graft function and injury was assessed 8 days post-transplantation.

Kidney function was measured by serum creatinine and urea levels and was
performed as mentioned above in section 2.8. The kidney graft was sectioned and
was either formalin fixed in 5% paraformaldehyde for histological assessment (see
section 2.13.) or flash frozen in liquid nitrogen for cellular infiltrate analysis.
Formalin fixed kidney sections were also stained for terminal deoxynucléotidyl
transferase dUTP nick end labelling (TUNEL) for apoptosis assessment in the kidney
(see section 2.14).

2.13.

Histology
Formalin fixed kidney sections were embedded in paraffin. Slides were then

cut at 5pm and stained with hematoxylin and eosin. Injury was scored in a blinded
fashion by a single pathologist (Dr. Bertha Garcia) using an arbitrary injury score
system (0: no change; l+:< 50% area change; 2+: >50% area change).

Injury was
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evaluated by the following major criteria with the sub-categories in brackets:
infiltrate (mononuclear cells and neutrophils), tubular changes (tubulitis and
necrosis), glomerular injury (necrosis and atrophy) and vascular injury (artery and
vein). Pictures were taken at either 40x or lOOx magnification on a Nikon H550L
microscope (Japan).

2.14.

TUNEL Assay
The TUNEL assay was performed with the Qia33

FragEL™

DNA

Fragmentation Detection Kit and instructions were followed as per manufacturer's
protocol (EMD Chemicals Inc, Gibbstown, USA).

Briefly, buffered formalin-fixed

kidney sections were processed with proteinase K (30 minutes at 37°C), followed by
quenching endogenous peroxidase in 3.0% H2O 2 in Tris buffered solution (TBS) (pH
7.4) for 30 minutes at room temperature. The section was then permeabilized with
0.20% Triton X-100 for 10 minutes at room temperature. Kidney sections were
incubated in Terminal Transferase (TdT) Reaction Buffer (25mM Tris-HCl, 200 mM
sodium cacodylate, 0.25 mg/ml BSA, Im M cobalt chloride) for 10 minutes. Kidney
sections were then incubated in TdT Reaction Mixture for 1-2 hours at 37-40 °C in a
humidified chamber.

Kidney sections were rinsed in stop wash buffer for 10

minutes to stop the reaction. Kidney sections were incubated with horse radish
peroxidise conjugated with streptavidin in TBS for 20 minutes at room temperature.
Kidney sections were incubated with DAB for 1-2 minutes. Tissue sections were
counterstained with methyl green for 30 seconds. Kidney sections were dehydrated
in 95% ethanol for 5 minutes and then in 100% ethanol for 3 minutes. Kidney
sections were dipped in xylene for 5 minutes, twice.

The kidney section was

mounted with xylene based mounting medium. The number of TUNEL-positive cells
representing apoptotic cells in each kidney section was counted in 5 non
overlapping fields under xlOO magnification and averaged in a blinded fashion.
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2.15.

Immunohistochemistry fo r Paraffin Embedded Kidney Sections
Paraffin fixed sections were deparaffinized in xylene and subsequently

dehydrated with 100% alcohol, 95% alcohol and 70% alcohol washes.

Tissue

sections were rinsed thoroughly under running tap water for 5 minutes. Tissue
sections were blocked for endogenous peroxidases using 3% H2O2 for 30 minutes.
Non-specific blocking of endogenous antigens in kidney cells was performed with
10% horse serum for 60 minutes and then subsequently drained and incubated with
rabbit anti-mouse-CD3 (1:50) (Dako, Burlington, ON) primary antibody for 60
minutes.

Primary antibody was then washed three times again with PBS. The

secondary antibody, anti-rabbit antibody (Dako) was then incubated with the slides
for 30 minutes. Freshly prepared 3,3'-diaminobenzidine (DAB) (Dako) was made
and incubated with the slides for one minute and quickly washed with tap water
after one minute. Sections were then counter stained with hematoxylin for five
minutes and then subsequently washed with tap water. Sections were dehydrated
by brief sequential application of 70%, 95% and 100% alcohol. Excess alcohol was
removed from the slides using 3 washes with xylene. Permount coverslips were
used to permanently seal sections on the positively charged slides.

Light

microscopy was used to visually to qualify the amount of CD3+ infilitrates.

2.16.

Immunohistochemistry fo r Snap Frozen Kidney Sections
The following protocol was used for snap frozen kidney to identify kidney

cellular infiltrates using primary antibodies against CD4, CD8, MAC-1, and B220.
Snap frozen kidneys were cut into 5pm sections and fixed in 100% cold acetone for
10 minutes. Non-specific blocking of endogenous antigens in kidney cells was
performed for 10 minutes. Kidney sections were incubated with 3% H2O2 for 10
minutes and then washed three times for 3 minutes with PBS. Kidney sections were
incubated with primary antibody (anti-CD4, anti-CD8, anti-MAC-1, and anti-B220)
for 60 minutes at room temperature. Kidney sections were washed three times for
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3 minutes with PBS. The secondary antibody was incubated with the kidney
sections for 30 minutes. Kidney sections were incubated with DAB until desired
stain intensity developed. Kidney sections were briefly washed with PBS and
counterstained with hematoxylin. Kidney sections were dehydrated by brief
sequential application of 70%, 95%, and 100% alcohol.

2.17.

Isolation o f Kidney Allograft Infiltrates
Protocol was performed as described by Wang et al. [151]. Briefly, kidney

grafts were minced and digested in collagenase D for 45 minutes (2mg/ml,
Worthington Biochemicals ©, Lakewood, NJ) in complete R P M I1640 media at 37°C.
The digested mixture was gently passed through a 40pm cell strainer (BD
Biosciences, San Jose, CA). The single cell suspension was then washed with HBSS
without Ca2+ or Mg2+ (Invitrogen Canada Inc, Burlington, ON] containing lOmmol/L
EDTA, 0.1% BSA, and lOmM HEPES buffer. Cell suspension was subjected to density
centrifugation [1500 rpm, no brakes, 30 minutes] using 1.083 g/ml Histopaque
(Sigma-Aldrich Canada, Oakville, ON] and the interphase that contained the
leukocytes were collected and washed with RPMI 1640 media [10% FBS] twice. The
leukocytes were resuspended in fluorescence activated cell sorting [FACS] staining
buffer (PBS with addition of 0.1% BSA, 0.09% sodium azide).

2.18.

Identifying CD4+CD25+FoxP3+ Populations in Kidney Allograft Infiltrate
To identify regulatory T cell populations in kidney allograft by flow

cytometry, Mouse Regulatory T Cell staining kit was used as described in
manufacturer’s protocol (eBioscience). Briefly, cells were stained with anti-CD4FITC (fluorescein isothiocyanate), and anti-CD25-PE (phycoerythrin) for 30min at
4°C in the dark. Cells were then fixed and permeablized with permeation solution
provided by the kit and stained used anti-FoxP3-APC (allophycocyanin) or isotype
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control antibody [PharMingen) for 30min at room temperature or 4°C overnight in
the dark. Cells were washed with permeabilization buffer and counted using the
cytomics FC 500 flow cytometer [Beckman Coulter).

2.19.

Statistical Analysis
Results are graphed as mean ± standard error of the mean (S.E.M). All

graphs with error bars in this report represent S.E.M. Statistical analyses were
performed using Microsoft Office Excel’s single factor ANOVA test and Student's Ttest The Log Rank Test was performed using the software, GraphPad [GraphPad
Software Inc., La Jolla, CA). Statistical significance was set at P £ 0.05.

32

3. Results
3.1.

Serum OPN Increases Following Kidney IR1 in B6 Mice
In the mouse kidney IRI model, we have demonstrated that OPN-/- kidneys

have reduced NK and macrophage infiltrates within the first 24 hours post kidney
IRI induction, and less injury as demonstrated by measurements of serum creatinine
[118]. The expression of OPN may therefore be required for attraction of cytotoxic
effector cells. As OPN is a known chemoattractant for macrophages, dendritic cells
and T cells, it is possible that the higher NK infiltration observed in OPN+/+ kidneys
subjected to IRI is related to kidney expression and systemic release of OPN. As the
production of OPN within the kidney might be substantial, our first objective was to
test if OPN could be detected within the circulation post IRI and whether the
changes in OPN levels correlate with the amount of injury detected in the kidney
post IRI by measuring serum creatinine. Blood samples of mice subjected to IRI
were tested for OPN at various time points using ELISA. An increase in OPN levels
can be observed in mouse serum following kidney ischemia as early as 8 hours.
Serum OPN correlated with kidney dysfunction as increases in OPN were
accompanied by increases in serum creatinine (Figure 1A and IB). Serum OPN was
found to be significantly increased at 24 hours after IRI induction (23.8 ± 3.1 ng/ml)
when compared with naive (7.9 ± 2.0 ng/ml, p<0.001) or sham (7.5 ± 1.5 ng/ml,
p<0.0001) mice (Figure 1A). Similarly, serum creatinine levels increased with time
following IRI and were found to be significantly increased at 24 hours after IRI (164
± 18 pmol/L) when compared to naive (22 ± 6 pmol/L, p<0.001) and sham
creatinine (16 ± 4 pmol/L, pcO.OOl) (Figure IB). These results support that OPN is
released by the kidney following kidney IRI.

Figure 1. Serum OPN and Serum Creatinine Increase w ith Tim e A fter IR I. The
left kidney renal artery and vein of a B6 mouse was clamped for 45 min and the
right kidney was subsequently removed after ischemia induction. Serum was then
collected from naive, sham, 0 ,1 , 2 ,4 , 8 and 24 hours after reperfusion and analyzed
for OPN and creatinine by ELISA. A) Serum OPN measured by ELISA increased
with time after IRI. Serum OPN was found to be significantly increased at 24 hours
after IRI induction (23.8 ± 3.1 ng/ml) when compared with naive (7.9 ± 2.0 ng/ml)
or sham (7.5 ± 1.5 ng/ml) mice (p=0.0006). B) Serum creatinine levels increased
with time following IRI and was found to be significantly increased at 24 hours
after IRI (164 ± 18 pmol/L) when compared to naive (22 ± 6 pmol/L) and sham
creatinine (16 ± 4 pmol/L) (p<0.0001). Naive group consisted of 3 mice. Mouse
groups sham, 0,1, 2, 4 and 8 hours consisted of 4 mice. The 24 hour mouse group
consisted of 8 mice. The data shown represent an average of at least three
independent experiments. Error bars shown represent S.E.M. Statistical analysis
employed the single factor ANOVA test and significance was set at p<0.05. (**) =
p<0.001, (***) = p<0.0001.
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3.2.

OPN Produced by TECs Influence N K Cell Chemotaxis
A previous study showed that OPN+/+ kidneys had greater NK cell infiltrate

than OPN-/- kidneys [118].

This study demonstrated that increased levels of OPN

were detected in the serum after IRI; suggesting that OPN is a chemotactic agent for
NK cells.

To establish the role of OPN produced by kidney TEC on NK cell

chemotaxis, we developed an in vitro chemotaxis model using primary TECs. The
first objective was to demonstrate that OPN+/+ TECs can produce OPN, while OPN-/TECs do not [117, 118, 143], The second objective was to show that inflammatory
stimuli that may mimic IRI in the kidney can induce OPN production by TECs.
Finally, the last objective was to determine ifO P N +/+ TECs can recruit NK cells more
efficiently than OPN-/- TECs.

3.2.i.

OPN+/+ TECs Produce OPN, but Not OPN/- TECs
TECs from both OPN+/+ and OPN'/' mice were isolated and cultured in vitro.

Culture supernatants were collected for ELISA to determine the presence of soluble
OPN.

TECs from B6 OPN+/+ mice express abundant OPN under normal culture

conditions. In distinct contrast, TECs from B6 OPN-/- mice expressed little or no OPN
(Figure 2).

3.2.H. Inflammatory Stimulus Can Induce OPN Production by TECs
To show that inflammatory stimuli similar to IRI in the kidney can induce
OPN production by TECs, various culture conditions were tested for changes in
soluble OPN levels. Treatment groups consisted of TECs bathed in K1 incomplete
media with: no treatment, addition of 5% FBS and 0.05 ng/ml EGF, increasing
concentrations of IL-2 (1.0, 5.0, 25.0 ng/ml), increasing concentrations of TNF-a
10.0, 20.0, 40.0 ng/ml) and increasing concentrations of IFN-y (5.0, 10.0, 20.0, 40.0
ng/ml). ELISA was used to detect secreted OPN in the supernatant after 24 hours of
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treatment. Media control consisted of K1 complete media in the absence of cells.
FBS and EGF supplementation to K1 incomplete media was found to stimulate TECs
significantly to produce OPN (30.0 ng/ml) when compared to the no treatment
control (only K1 incomplete media) (16.6 ng/ml, P < 0.001) (Figure 3).

TEC-

induced OPN production can also be stimulated by TNF-a or IFN-y treatment. TECs
treated with TNF-a (5, 10, 20, and 40 ng/ml) resulted in significant production of
OPN at levels between 27.3 to 32.1 ng/ml of OPN when compared to no treatment
conditions (p<0.001). Similarly, addition of IFN-y (5,10, 20, and 40 ng/ml) resulted
in significant amounts of OPN detected in the supernatant at levels starting at 36.7
ng/ml and decreasing to 27.7 ng/ml when compared to no treatment conditions
(pcO.001). IL-2 treatment did not stimulate TECs to secrete any significant amounts
of soluble OPN. No dose-dependent response was observed with any treatment of
cytokines. Therefore, culture conditions and inflammatory stimulus can influence
TEC production of OPN. However, the OPN detected using ELISA does not confirm
biological function.

Figure 2. OPN+/+ TEC Produce OPN, B ut Not OPN-/- TEC. TECs were plated at
various concentrations (1x10s, 2x10s and 4x10s) and ELISA was used to detect
secreted OPN in the supernatant of both OPN+/+ and OPN-/- TECs after 24 hours of
culture. OPN+/+ TECs produce OPN in significant amounts compared to OPN-/TECs. Statistical analysis was performed with Student’s T-Test n = 3 ***p<0.001
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Figure 3. OPN Expression in TECs Increase in Response to EGF, T N F-a and
IFN-y, bu t Not IL-2 Treatm ents. Treatment groups consisted of TECs bathed in
K1 incomplete media with: no treatment, addition of 5% FBS and 0.05 ng/ml EGF,
increasing concentrations of IL-2 (1.0,5.0,25.0 ng/ml), increasing concentrations
of TNF-a (5.0,10.0,20.0,40.0 ng/ml) and increasing concentrations of IFN-y (5.0,
10.0, 20.0, 40.0 ng/ml). ELISA was used to detect secreted OPN in the
supernatant 24 hours later. TECs without treatment (only K1 incomplete media)
produced 16.6 ng/ml OPN. Significant amounts of OPN (30.0 ng/ml, p<0.001)
were produced by TECs when growth factors (EGF and FBS) were added.
Addition of TNF-a resulted in significant production of OPN at levels between
27.3 to 32.1 ng/ml (pcO.001). Addition of IFN-y resulted in significant levels of
OPN detected, starting from 36.7 ng/ml and decreased to 27.7 ng/ml (pcO.001).
No dose dependent response was observed with any treatment of cytokines. IL-2
treatment did not stimulate TECs to secrete any significant amounts of soluble
OPN. The media control consisted of K1 complete media in the absence of cells.
Statistical analysis was performed with the single factor ANOVA te st Please note
standard error bars were too small to be seen, n = 4 ***p<0.001
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3.2.M. OPN*/* TECs Mediate Greater NK Cells Chemotaxis than O P N T E C s
OPN's function as an adhesion or chemotactic agent can be tested by using
the cell adhesion test or chemotaxis chambers [105, 118]. OPN produced by TECs
was tested for its capacity to attract NK cells across semi-permeable membranes in
transwell chemotaxis assays. OPN+/+ TECs consistently attracted significantly more
NK cells than OPN’/- cells (7.8 ± 1.7 versus 4.2 ± 0.6, p < 0.05) (Figure 4). To confirm
that a difference in observed NK migration was caused by OPN, neutralizing antiOPN antibodies (5 pg/ml) were added to the TECs one hour before the chemotaxis
assay. Of note, anti-OPN antibody consistently (n= 4 experiments) failed to inhibit
NK cell chemotaxis using either OPN+/+ or OPN-/- TECs (Figure 4). We then tested
whether rmOPN was a chemotactic agent for NK cells directly.

Various

concentrations of rmOPN were used (0 - 2.5 pg/ml), but no significant chemotaxis
of NK cells towards rmOPN was observed (Figure 5). These results suggest that
while OPN expression by TECs was involved in the chemotaxis of NK cells, the effect
was not through a direct mechanism.
As OPN+/+ TECs clearly and consistently demonstrated a greater chemotactic
effect on NK cells than OPN-/- TECs, and rmOPN had no effect on NK cells directly,
we tested whether the chemotactic ability of OPN-/- TECs could be restored by
supplementation

of rmOPN.

OPN-/- TECs were treated with

increasing

concentrations of rmOPN (0.1-5.0 pg/ml) for 24 hours prior to performing
chemotaxis assays with NK cells.

Addition of rmOPN to OPN-/- TECs resulted in a

modest but significant increase in NK chemoattraction (Figure 6) albeit at relatively
high concentrations of rmOPN. These results suggest that OPN expression by TECs
might have an indirect effect on the chemotaxis of NK cells. Therefore, OPN may
induce TEC expression of known NK chemokines such as MCP-1, M IP-la, IP-10,
RANTES, and CX3CL1.

Figure 4 . OPN+/+ TECs Induce a G reater Chem otactic Effect on NK C ells than
OPN-/- t e c s . NK cells were labelled with 0.5pM of CFDA-se. NK cells were then
loaded at 10s in the upper chamber separated by a 5 pm polycarbonate
membrane. OPN-/- or OPN+/+ TECs were plated in the lower chamber at 2x10s
cells. Two hours of chemotaxis was allowed to occur. Flow cytometry was used
to quantify the number of CFDA-se positive cells in the lower chamber. CFDA-se
positive NK cells in the lower chamber were considered to be successful
migrants. OPN+/+ TECs was shown to cause significantly higher migration o f NK
cells than OPN-/- TECs. Furthermore, neutralizing antibodies (5 pg/ml) against
OPN did not inhibit NK cell migration. The negative control consisted of NK cells
migrating towards the lower chamber with only K1 incomplete media. Error
bars shown represent S.E.M. Statistical analysis performed with Student’s T-T est
This data is representative of four experiments. *p<0.05
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Figure 5. R ecom binant M ouse O steopontin is Not a Chem oattractant fo r NK
Cells. NK cells were loaded (10s cells) on the upper chamber of 5pM
polycarbonate transwells with increasing concentrations of rmOPN (0 - 2.5
pg/ml) in the lower chamber. Two hours of chemotaxis was allowed to occur.
Flow cytometry was used to quantify the number of migrated cells in the lower
chamber. An increasing concentration of rmOPN treatment did not result in a
dose dependent NK cell migration. Error bars shown represent S.E.M. The
results shown here are pooled from 3 separate experiments that have been
normalized to the media control.
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Figure 6.
R ecom binant M ouse O steopontin P artially R estores NK
Chem otactic A b ility to OPN'/- TEC. OPN-/- TECs were treated with increasing
doses of rmOPN (O.lpg/m l to 5pg/ml) for 24 hours prior to chemotaxis assay.
The NK cells were stained with CFDA-se (0.5 pM) prior to the chemotaxis assay.
NK cells were loaded into the upper chambers of 0.4pm pore size transwells with
OPN-/- TECs in the lower chamber and two hours were allowed for chemotaxis to
occur. CFDA-se positive cells in the lower chamber were analyzed by flow
cytometry. A significant increased migration of NK cells was observed with
increasing concentration of rmOPN added to the OPN-/* TECs (n = 3). Error bars
shown represent S.E.M. Statistical analysis was performed with Student's T-test
*p<0.05, **p<0.005
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3.3.

Recombinant OPN Differentially Alters Chemokine Expression in OPN-/- and
OPN+/+ TECs
To test whether OPN can alter NK cell recruitment by indirectly regulating

TEC chemokine expression, primary OPN-/- and OPN+/+ TECs were exposed to
rmOPN for 12 hours. Total RNA was then extracted for qPCR analysis of known NK
chemokines including MCP-1, IP-10, M IP-la, RANTES, and CX3CL1. In addition, IRI
associated chemokines such as midikine (MK) and kératinocyte derived chemokine
(KC) were included in the screening panel. Recombinant mouse OPN exerted a
trend to increase chemokine mRNA expression in OPN-/- TECs apart from KC which
was reduced at 500 ng/ml (p < 0.05) (Figure 7). In contrast, rmOPN had a general
suppressive effect on chemokine mRNA levels in OPN+/+ TECs (Figure 7). Although
these data do not show a robust NK chemokine expression in response to rmOPN
treatments in TECs, it suggests that the exogenous supplementation of rmOPN
influenced chemokine expression in TECs.

Figure 7. Recom binant M ouse OPN Enhances Chem okine Expression in
OPN-/- TEC Com pared to OPN+/+ TEC. Kidney TECs from OPN'/- or OPN+/+ mice
were treated with rmOPN at 0, 0.005, 0.05, 0.5pg/ml in incomplete K1 media.
Total RNA was extracted after 12 hours of culture and qPCR was done to analyze
the following chemokine transcripts: MCP-1, M IP -la, IP-10, RANTES, CXC3L1,
MK, and KC. A) OPN-/- TECs treated with rmOPN at increasing doses appeared to
increase MCP-1, IP-10, M IP -la, RANTES and CXC3L1 mRNA. With exception to
CXC3L1, OPN+/+ TECs generally showed suppressed chemokine expression with
increasing doses of rmOPN treatments. B) IRI associated chemokines KC and
MK mRNA were respectively found to be suppressed and unchanged with
increasing doses of rmOPN treatment on OPN-/- TECs. Panel C) represents an
alternate view for chemokine expression trend comparisons between OPN+/+ and
OPN-6- TEC. It should be noted that the starting mRNA product between
genotypes were not equivalent The data points of OPN-/- and OPN+/+ were
plotted on the same graph to show trend of chemokine expression change with
increasing concentrations of rmOPN treatment. Chemokine expressions were
normalized to no treatment rmOPN as a baseline control. The percent change in
chemokine mRNA for OPN-/- and OPN+/+ TECs are represented as red and blue
lines respectively. The results shown are representative of three independent
experiments.
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3.4.

OPN Does Not Alter Survival o f Mouse TECs in Response to Inflammatory
Cytokines (TNF-a and IFN-y) and/or Hypoxia
IRI is an important aspect of acute kidney injury. For kidney function to be

maintained, the survival of kidney cells is required. Previous studies have shown
OPN providing a survival benefit to non-kidney cell types [122,124,130,133]. The
potential effect of OPN on inflammatoiy and hypoxic injury on TECs survival has not
been studied. TEC in response to hypoxia as well as exposure to the inflammatory
cytokines TNF-a and IFN-y in vitro undergo apoptotic cell death. OPN-/- and OPN+/+
TECs were subjected to TNF-a, IFN-y, and/or hypoxia and then evaluated for
apoptosis and necrosis by flow cytometry using AV and PI staining [Figure 8).
/
Hypoxia and inflammatory cytokines effectively induced cell death when compared
to the no treatment control. However, there was no significant difference in the
level of cell death (top right quadrant] after death inducing conditions when
compared to no treatment controls in each respective cell type. Furthermore the
addition of rmOPN provided no survival benefits to TECs of both cells.

Under

hypoxic and cytokine treatments, OPN+/+ TECs had 33% increase in cell death and
34% cell death with addition or rmOPN. Under similar conditions, OPN /- TECs had
35% increase in cell death and 36% cell death with addition of rmOPN. Collectively,
these data strongly suggest that OPN did not confer a survival benefit to TECs.

Figure 8. OPN Does Not Improve the Survival of TECs Exposed to
Inflammatory Cytokines (TNF-a and IFN-y) or Hypoxia. Primary B6 TECs
were isolated from a A) OPN+/+ or B) OPN-/- mouse and were cultured to 70-80%
confluency in complete K1 media. Treatment group consists of TECs in
incomplete K1 media with: no treatment, hypoxia, hypoxia with TNF-a and IFN-y,
and hypoxia with TNF-a, IFN-y and rmOPN. TECs were serum starved for 24
hours in incomplete K1 media. Note: In treatment groups that included rmOPN
(2pg/ml) treatment, it was added 24 hours prior to hypoxia and cytokine
treatments. TECs were subsequently treated with TNF-a (20ng/ml) and IFN-y
(20ng/ml) for 24 hours.
Cell death was quantified 24 hours later by flow
cytometry using PI and AV staining. There was no significant difference in cell
death patterns between 0PN+/+ and OPN-/- TECs with cytokine treatments: even
with addition of rmOPN. The data shown was a representative of three
independent experiments.
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3.5.

Loss o f Donor Kidney OPN Worsens Allograft Function and Increases Risk o f

Rejection
We have previously shown that the loss of OPN attenuates IR1 and reduces
NK cell infiltration into post ischemic kidneys. This may relate to an indirect effect of
OPN on as yet unidentified endogenous chemotactic factors expressed by kidney
cells. These results suggested that the elimination of OPN might be beneficial in
transplantation as 1RI is an important component of transplant injury. To test if
donor kidney expression of OPN alters graft function, a fully mismatched allogenic
kidney transplant model was used.

As previously stated, OPN-/' mice are

phenotypically normal and have no obvious abnormalities in renal function or
kidney development.

B6 OPN-/- kidneys served as donor kidneys and were

transplanted into recipient Balb/c (H2d) mice that have been dual nephrectomized.
B6 OPN+/+ donor kidneys were similarly transplanted into Balb/c recipients and
served as controls. These models thus rely on the transplanted kidneys for renal
function.
Eight days post-transplantation, kidney function was assessed by serum
creatinine and urea. OPN-/- transplanted kidney recipients had significantly higher
serum creatinine (110.1 pmol/L ± 36.4 vs. 26.0 pmol/L ± 2.8, p< 0.019) (Figure 9A)
and urea (49.0 mmol/L ± 14.4 vs. 20.4 mmol/L ± 2.0, p< 0.033) compared to 0PN+/+
kidneys (Figure 9B). Histopathology was used to evaluate structure and correlate
observed elevated serum creatinine levels and reduced function to the degree of
infiltrate and injury in renal parenchymal cells. Kidney allograft sections from Day 8
were stained with haematoxylin and eosin for pathological analyses (Figure 10A).
Kidney sections were scored by a transplant pathologist, Dr. Bertha Garcia, in a
blinded manner.

Injury was evaluated using a previously reported semi-

quantitative score (refer to section 2.13) which assesses infiltrate (mononuclear
cells and neutrophils), tubular changes (tubulitis and necrosis), glomerular injury
(necrosis and atrophy) and vascular injury (artery and vein).
number indicated greater injury.

A higher score

Consistent with elevated urea and creatinine
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levels, OPN'/' donor kidneys had a higher overall score (all the categories averaged]
of 0.84 ± 0.04, when compared to OPN+/+ kidneys which scored 0.44 ± 0.11 (p<
0.005] (Figure 10B].

Specifically, greater infiltration of mononuclear cells was

evident in OPN'/* donor kidney grafts (Figure 10C) as well as more pronounced
arterial damage (Figure 10F). Immunohistochemistry (IHC) was used to profile the
increased infiltrate observed with OPN-/- kidneys. Using anti-CD3 antibody, there
was an increase in the numbers of CD3+T cells in OPN-/- kidney grafts compared to
OPN+/+ kidney grafts (Figure 11).

The CD3+ infiltrating cells appeared to be more

intensely concentrated in the interstitium between TECs and blood vessels. The use
of frozen sections resulted in poor staining resolution for CD4, CD8, MAC-1, and
B220. Thus, no quantifiable differences in mononuclear infiltrates were observed
between OPN-/- and OPN+/+ kidney grafts.

Figure 9. OPN'/' Donor Kidneys had Worse Function than OPN+/+ Donor
Kidneys when Transplanted into Nephrectomized Balb/c Recipients. Balb/c
mice were dual nephrectomized and received a single B6 OPN+/+ or OPN'A donor
kidney. Serum creatinine and urea was measured 8 days post-transplantation. A)
Serum creatinine was significantly higher in recipients with OPN'/- kidneys
(white bars) when compared to OPN+/+ kidneys (cross hatched) with
measurements of 110.1 pmol/L ± 36.4 and 26 pmol/L ± 2.8, respectively (p <
0.019). B) Urea was also higher in recipients with OPN /' kidneys (white bars) in
comparison to 0PN+/+ kidneys (cross hatched) with values of 49.0 mmol/L ± 14.4
and 20.4 mmol/L ± 2.0, respectively (p < 0.033). Error bars shown represent
S.E.M. Statistical analysis was performed with student's T-Test. Each group
consisted of eight mice. *p < 0.05.
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Figure 10. OPN-/- Donor Kidneys had Greater Injury than OPN+/+
Donor Kidneys. Balb/c mice were dual nephrectomized and received a single
B6 OPN+/+ or OPN-/- donor kidney. A) 0PN+/+ or OPN-/- kidney sections were
taken from either naive (left column) or 8 days post transplantation mice
(right column) and were stained with hematoxylin and eosin. There were no
infiltrating cells in the naive mouse kidneys of both genotypes (left column).
However, there was more apparent mononuclear infiltrate (arrows) in the
OPN-/- kidney graft (lower right picture) than the 0PN+/+ kidney (top right
picture). Pictures were taken in the medulla region of the kidney (in view of
one or more glomeruli) at lOOx magnification.
Kidney sections were scored by a pathologist using an arbitrary grading
scale,from 0 to 2. A score of 0 represented no injury, and 2 represented severe
injury. B) OPN-/- transplanted kidneys received a higher overall injury score
(all the categories averaged) of 0.84 ± 0.045, when compared to OPN+/+
kidneys that had a score of 0.43 ± 0.112 (p < 0.005). Overall injury score for
Balb/c syngenic transplant was negligible and was not shown. C) There was a
significant increase in the number of observable mononuclear infiltrate in the
OPN-/- kidneys versus the 0PN+/+ kidneys (p<0.016). D) No significant injury
was observed in the glomeruli between the OPN+/+ and OPN-/- kidney grafts. E)
There was no significant difference in tubular injury between OPN+/+ and OPN/- kidney grafts. F) Significant injuries were found in the arteries of OPN /kidneys when compared to the OPN+/+ kidneys (p < 0.006), but not in the veins.
The following describes the number of single kidney transplants into Balb/c
recipient mouse: syngenic control consisted of one Balb/c kidney, allogenic
OPN+/+ donors consisted of seven B6 kidneys, and the allogenic OPN-/- donors
consisted of six B6 kidneys. Error bars shown represent S.E.M. Statistical
analysis was performed with student’s T-Test. *p < 0.05, **p < 0.005
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OPN has been shown to act as a differentiation factor for dendritic cells and T
cells. We tested whether the loss of donor kidney OPN had an in situ effect on intragraft regulatory T cells which might account for the increased infiltrate and
rejection, as a result of augmented alloimmunity.

Kidney graft infiltrates were

isolated from kidney allografts and tested for the presence of CD4+CD25+FoxP3+
cells 8 days post transplantation (Figure 13). There were no differences detected in
the numbers of Treg cells in OPN+/+ and OPN'/- kidney allografts, however, their
ability to function as regulatory cells was not tested.
While we did not observe any benefit of OPN on TEC survival in vitro, it
remains possible that TECs and other parenchymal cells require OPN in the donor
kidney for cell survival in vivo. To test if increased apoptosis of kidney cells might
account for kidney dysfunction and elevated serum creatinine, TUNEL staining was
performed on kidney sections to quantitatively assess apoptosis. Overall greater
TUNEL positivity was evident in OPN'/- as compared to OPN+/+ kidney grafts (231 ±
65.0 cells vs. 84 ± 10 cells, p < 0.04) (Figure 12). The increased frequency of TUNEL
positive cells undergoing apoptosis was best appreciated at lOOx magnification.
While it is not possible to unequivocally determine the identity of TUNEL positive
cells in these analyses, it appeared that the predominant cells type undergoing
apoptosis were infiltrating cells. However, it should be noted that it was difficult to
clearly identify if the apoptotic cells were TECs or immune cell infiltrates.

Figure 11.
Im m unohistochem istry P rofiling For Kidney Infiltrates at 8
Days Post-Transplantation. Balb/c mice (recipient) were dual nephrectomized
and received one kidney from either B6 OPN+/+ or OPNV- mice (donor). Kidney
grafts were taken 8 days post-transplantation. A) Paraffin sections of kidney
grafts were stained for CD3. There appeared to be more CD3 positive cells
(arrows) in the OPN-/- grafts when compared to OPN+/+ kidney grafts. B) Snap
frozen kidney graft sections were stained for CD8, 4, MAC-1, and B220. Pictures
were taken at lOOx magnification and are representative of 5 random fields of
view in the kidney. No definitive difference could be found with CD4, CD8, MAC1 and B220 stains. n=2 for CD3 stains, and n=3 for the frozen section.
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Figure 12. Greater Apoptosis Was Detected in OPN'/- Kidneys Com pared to
OPN+/+ Kidney 8 Days Post-Transplantation. Balb/c mice (recipient) were
dual nephrectomized and received one kidney from either B6 OPN+/+ or OPN-/mice (donor). Kidney grafts were taken 8 days post-transplantation and
analyzed for apoptotic death via TUNEL staining. TUNEL positive stains are
indicated with arrows (brown dots). A) OPN-/- kidney grafts had greater TUNEL
positive stains than OPN+/+ kidney grafts (right column, p < 0.04). TUNEL positive
spots were counted by the software using area and staining intensity as
parameters during quantification. Quantification was done at lOOx magnification
using five random fields of view in the medullary region of the kidney by using
the presence of one or more glomeruli as reference points. Pictures shown in the
first row are taken at 40x to give a general overview of the medulla section of the
kidney. Second row pictures were taken at lOOx to show relative locations of
TUNEL positive cells. B) A picture of a rejected kidney is stained heavily by
TUNEL. C) There is significantly more TUNEL positive cells in OPN-/- grafts (231
± 65 cells) (white bars) when compared to OPN+/+ grafts (84 ± 10 cells)(cross
hatched bars) (*, p < 0.05). TUNEL staining appeared to be more frequent in the
interstitium. Error bars shown represent S.E.M. Statistical analysis was
performed with student's T-Test. n = 3 for B6 OPN+/+, n = 5 for B6 OPN"/-.
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Figure 13. CD4+CD25+FoxP3+ Infiltrating Cell Populations were Not Altered
in OPN+/+ or OPN*/- Donor Kidneys 8 Days Post-Transplantation. Balb/c mice
(recipient) were dual nephrectomized and received one kidney from either B6
OPN+/+ or OPN-/- mice (donor). Kidney grafts were analyzed at day 8 for the
presence of CD4+CD25+FoxP3+ cells by Ficoll density gradient purification and
subsequently stained for CD4+ (FITC), CD25+ (PE). Intracellular protocols were
employed for FoxP3+ (APC) staining. Splenocytes were used as staining controls.
The gating strategy used involved gating on CD4+, and CD25+ cells before plotting
for CD4+FoxP3+ cells.
Flow cytometry revealed no difference in
CD4+CD25+FoxP3+ cell populations in both mouse strains. Data represents one of
three independent experiments.
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3.6.

O P N K i d n e y Allografts Had Worse Survival than OPN+/+ Kidney Allografts
Finally, the role of donor kidney OPN in maintaining the long term survival of

kidney allografts was tested using OPNV- (n = 10) and OPN+/+ (n = 8) donor kidney
(H2b) into Balb/c mouse (H2d) recipients. As recipients were fully nephrectomized,
survival was entirely dependent on the function of the transplanted kidneys. Mice
were monitored daily and were euthanized if clinical deterioration was detected
(refer to section 2.11 for euthanasia criteria). OPN'/- kidney donor grafts had
significantly reduced survival when compared to OPN+/+ grafts (p=0.0065) (Figure
14). Fifty percent of the OPN-/- kidneys failed within 10 days post-transplantation,
while another 25% of the grafts failed within 20 days.

Figure 14. OPN-/- Kidney Allografts Had Worse Survival than OPN+/+
Kidney Allografts. Balb/c mice were dual nephrectomized and received a single
B6 OPN+/+ or B6 OPN-/- donor kidney. The health of the transplant mouse was
subsequently monitored daily and sacrificed if dramatic deterioration of health
was detected. OPN+/+ donor grafts survived significantly better than OPN'/- (Log
Rank Test, p = 0.0065). Median survival of OPNV- was 14 days, n = 8 for OPN+A
kidney grafts, n = 10 for OPN-/- kidney grafts.
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4. Piscussion
4.1.

Summary
Previous studies have linked kidney expression of OPN to IRI as OPN'/-

kidneys have significantly less injury [117,118,143]. In our studies, we have found
that OPN was significantly elevated in serum 24 hours following IRI and correlated
with peak serum creatinine levels.

OPN contributes to kidney IRI through

recruitment of NK cells [34,118]. OPN-/- TECs had a significantly reduced capacity
to attract NK cells [Fig. 4). OPN-mediated chemotaxis of NK cells appeared to exert
its effect through indirect regulation of TEC chemokine expression (Fig. 7).
Furthermore, we tested the role of OPN in kidney transplantation. OPN-/- kidney
donor grafts had significantly more injury, worse survival and function (Fig. 9-11,
14).
Collectively these results support an important but complex role of OPN in
kidney inflammatory injury. While the absence of OPN improves kidney IRI possibly
through an indirect effect on NK cell chemotaxis, the elimination of kidney
expressed OPN may not benefit transplantation due to the possible alterations in the
regulatory pathways that suppress rejection. These results are important for future
consideration in therapeutic strategies for renal transplantation that involves the
manipulation of OPN.

4.2.

OPN Likely Acts as an Indirect Regulator o fN K Chemokine Expression in TECs
Our understanding of long term survival of kidney transplants is incomplete

and yet is of critical importance to many patients. Various factors influence the long
term survival of kidney transplants including the invariable injury of the kidney that
occurs during procurement prior to transplantation, IRI following re-establishment
of blood supply, immunological rejection, and the balance between persistent
inflammation and mechanisms of repair. While short term acceptance of kidney

75

transplants (ie. 1 year survival] has improved due to the advancement of anti
rejection drugs [152], there has been little advancement in long term survival of
kidney grafts. While many reasons may be responsible, greater attention is being
drawn to our lack of effective therapies that can target innate immunity and chronic
inflammation. It may be possible that persistent inflammation within the kidney
results in progressive and eventually irreversible loss of kidney cells that cannot be
addressed by endogenous mechanisms of repair. This results in loss of function and
the graft. NK cells are important cytotoxic effector cells of innate immunity, which
are increasingly recognized for participation in acute and chronic injury, and there
no known

effective

anti-rejection

drugs

that

can

control

them.

In a

tolerance/survival mouse cardiac allograft model, the use of anti CD28 antibody
eliminated cytotoxic T cells but did not allow indefinite survival of the kidney graft
without elimination of NK cells as well [128].

This suggests that effector

mechanisms of chronic injury may include diverse cell types not controlled by
current immunosuppression, and NK cells are under appreciated for their role in
kidney injury. In our study, as well as others [34,118], there is evidence of NK cells
contributing to kidney IRI.

Hence, the control of NK cells may be of great

importance in reducing graft injury and promoting long term graft survival.
TECs are a major cell type in the kidney and if a critical number of TECs are
lost due to injury and are not regenerated, loss of function results in the kidney. It is
known that cell death can be induced in TECs by a number of cytokines produced by
inflammatory cells or effector mechanisms of cytotoxic cells such as NK and CD8+ T
cells which kill by Fas-FasL interactions, and Prf/GrB. Well described examples of
TEC apoptosis induced by inflammatory cytokines via caspase-8 activation are IFN-y
and TNF-a [39, 40].
induction [34].

NK cells can induce TEC death by Prf/GrB following IRI

Furthermore, TECs can increase the expression of the NK cell

activation ligand, Rae-1 after IRI and that blockade of either Rae-1 or its NK cell
receptor, NKG2D, can abrogate NK cell induced TEC apoptosis [34], In addition
TECs are clearly able to recruit immune cells by their expression and release of
chemokines. The chemokines, MCP-1, IP-10, M IP-la, RANTES and CX3CL1 have
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been implicated as NK chemokines and have been shown to be up-regulated during
kidney IRI [30, 153, 154],

Thus, TECs following injury are likely capable of

recruiting NK and other effector cells which in turn can further potentiate TEC
As IRI in transplantation is unavoidable with procurement of the donor organ, NK
cells may play an important acute and chronic role in kidney transplant injury.
OPN may be a protein that regulates cell injury but it has not been studied in
detail in TECs. OPN is a multi-functional secreted phosphoprotein that can influence
a diverse population of cells. OPN expression can be found in almost every cell type
of the body. OPN can be expressed by many cell types such as activated T cells,
macrophages, dendritic cells and endothelial cells [102, 104, 123, 141, 142].
However the greatest expression has been found in bone and epithelial tissues
[104]. OPN expression is increased in response to cellular stress in a variety of renal
diseases, as well as breast cancer and atherosclerosis [155-158]. While OPN is
produced in the kidney and is rapidly up-regulated during injury [117, 118, 143,
149], the primary cell types producing OPN in the kidney have not been
characterized.

However, TECs have been

shown to express OPN in an

immunohistological study [118]. OPN has been found to possess pro-inflammatory
cytokine like properties, anti-apoptosis and chemotactic activity, and wound healing
abilities for a variety of cell types in mouse models in vivo [120,122,127,159].
Genetic targeting of OPN has been described in mice. OPN-/- mice are
phenotypically normal and are fertile [150], but are more susceptible to viral and
intracellular infections. Interestingly they also have a reduced ability to mount T h l
responses [137, 140], In regard to kidney related injury models, OPN has been
identified as a factor that can both promote injury and protect the kidney. Increased
OPN expression and secretion in acute injury models such as IRI or UUO was
correlated with increased fibrosis and kidney injury. These injury models also noted
an increased infiltration of inflammatory cells such monocytes, macrophage, and NK
cells [34, 117, 127, 149]. Zhang et al. have found that OPN-/- mouse kidneys after
had less acute NK cell infiltration than OPN+/+ kidneys [118]. IHC demonstrated a
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substantial increase in OPN expression within the tubule-interstitial areas after 1RI
suggesting TECs may be a source of OPN that attracts effector cells to cause injury
[118]. In this study, we have found that OPN produced by TECs play a role in NK
migration (Figure 2-4). This data supports the concept that NK cells play an integral
role in kidney injury, and that OPN may regulate inflammatory injury in the kidney.
Based on previous studies of NK injury and the absence of detailed studies of
TEC expression of OPN, it is important to study mechanisms by which this cytokine
might participate in NK cell recruitment to the kidney after transplantation. OPN
has been identified as a chemotactic agent for monocytes, macrophages, dendritic
cells and T cells [131,160-162]. However, it is not clear if this chemotactic property
applies to NK cells. OPN has been identified to have anti-apoptosis activity for many
of these same cells including macrophages, dendritic cells, and T cells [102, 115,
123, 161], possibly by inhibition of nitric oxide induced apoptosis [138]. OPN has
not been found to provide survival benefits to TECs under inflammatory conditions.
As TECs are a major cell population of the kidney and thus, critical to the overall
function, the expression of OPN by TECs and its role in altering kidney transplant
injury was investigated. These studies were undertaken to test the hypothesis that
kidney TEC expression of OPN contributes to hypoxic and inflammatory kidney cell
injury. Specifically, this study tested the role of kidney TEC expressed OPN on the
chemotaxis of NK cells, a recently identified effector of IRI, as well as the role of OPN
as a survival factor for TEC in vitro and in vivo following mouse kidney
transplantation.
It has been reported that OPN levels are inversely correlated to glomerular
filtration rate (GFR) and might reflect kidney stress [163]. In the present study, we
confirmed that OPN could be detected in serum after IRI (Figure 1) [163]. Serum
OPN was detected as early as eight hours post IRI (14.5 ng/ml,) when compared to
sham (7.5ng/ml, p= 0.65).

The highest level OPN expression (23.8 ± 3.1 ng/ml)

within the 24 hour study period correlated with the highest serum creatinine level
(164 ± 18.3 pl/L) as was seen in another rat IRI model [143]. The small size of OPN
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(33 to 44 kDa] may permit kidney clearance by simple filtration, and may account
for our results of higher OPN in mice with impaired kidney filtration. We did not
measure urine OPN which would have clarified this point. However, as OPN
increased within hours of IRI prior to any changes in creatinine, it is unlikely that
only impaired filtration could account for OPN increases in serum and that a
substantial kidney production increase of OPN was involved. Detailed analysis of
urine OPN following IRI would be required to assess this.
In addition, in vitro experiments confirm that TECs produce OPN (Figure
2)[118]. As expected, B6 OPN+/+ TECs were found to express high basal levels of
soluble OPN (20ng/ml per 10s cells), while B6 OPN-/- TECS had essentially
undetectable levels of OPN (Figure 2).

Very low levels of OPN in the OPNV-

supernatants most likely resulted from non-specific binding and were also reported
by other groups using this methodology [150]. ELISA testing also showed that OPN
production by B6 TECs was enhanced by TNF-a and IFN-y treatments but not IL-2
(Figure 3). Although a clear dose response of OPN production following cytokine
treatment was not observed as levels plateaued, it is possible that the
concentrations of OPN selected were too high and resulted in near maximal OPN
production. Both TNF-a and IFN-y represent inflammatory cytokines detected in
the kidney during IRI and kidney rejection, and our data suggests that inflammation
may similarly increase the expression of OPN by TECs in vivo. Nonetheless, the
renal source and abundance of OPN following injury and its known chemotactic
capacity for many immune cells, raises the possibility that OPN similarly influences
NK infiltration into the kidney.

Thus, regulation of TEC expressed OPN may

potentially be a therapeutic strategy to reduce inflammation induced by cytotoxic
cells such as NK cells in transplants. Indeed, absence of kidney OPN is associated
with reduced kidney IRI [117,118,143].
Following IRI in the kidney, there is an influx of cells including NK cells.
Although TECs express OPN which is enhanced by inflammatory cytokines and OPN
has chemotactic activity for monocytes and macrophages in the kidney [120,127], it
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was not known if OPN plays a role in the chemoattraction of NK cells. This was
tested in an in vitro model. OPN-/- and OPN+/+ primary TEC cultures were used to
test their ability to attract NK cells. In repeated experiments, OPN+/+ TECs had an
approximately two fold greater ability to attract NK cells than OPN-/- TECs (Figure
We attempted to confirm whether OPN was directly chemotactic by the addition of
neutralizing anti-OPN antibodies. Surprisingly, the addition of anti-OPN antibodies
to TEC cultures did not affect NK migration.

Various lengths of time and

concentrations of neutralizing antibodies were tested (data not shown], as well as
pre-treatment of TECs but NK migration was unchanged in OPN+/+ TEC cultures.
While the reason for which the neutralization of OPN was ineffective remains
unknown, it is possible that the neutralizing antibody available to us did not target
the chemotactic region (i.e the RGD domain) responsible for chemotaxis effects.
More likely, TECs are able to produce NK chemoattractants both dependent and
independent of TEC produced OPN. Indeed OPN-/- TECs were able to attract low
numbers of NK cells despite the inability to produce wild type OPN. To further study
this, we tested direct chemotaxis of NK cells to rmOPN and the effect of NK cell
chemotaxis in OPN-/- TEC cultures supplemented with increasing doses of rmOPN.
A wide range of rmOPN concentrations were tested (0-2.5 pg/ml) in direct
chemotaxis assays of NK cells to rmOPN. NK cells did not migrate to rmOPN in a
dose response fashion regardless of concentration (Figure 5). While this supports
the concept that OPN is not directly chemotactic for NK cells, it may be possible that
the rmOPN form lacks the necessary post translational modifications which occur at
the cell surface by MMP family enzymes. OPN is a substrate for many enzymes such
as thrombin, stromelysin-1 (MMP-3) and matreylsin (MMP-7) [109, 111]. It has also
been shown that during kidney injury, increased expression of MMP-7 occurs at the
TEC surface [164]. Cleavage of OPN by MMP-3 or MMP-7 results in the generation
of N-terminal fragments that contain an exposed RGD domain that mediates many
known chemotactic functions for macrophages [111].

To clarify this, detailed
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testing with exposure of rmOPN to MMP digestion may be required but was not
done in this study.
Next, we tested if OPN had an indirect effect on TEC attraction of NK cells.
OPN-/- TECs were thus tested to determine whether NK chemoattraction could be
"rescued" by rmOPN supplementation. Moderate recovery of NK attraction by OPN/- TECs was indeed observed when TECs were supplied with rmOPN (Figure 6) but
was not as high as observed with OPN+/+ TECs.

Several explanations may be

considered for the lack of full recovery of NK chemoattraction after rmOPN
supplementation. OPN itself can be extensively post-translationally modified [102,
104,165, 166] and it may be possible that the rmOPN supplied to OPN-/- TECs may
not be completely processed or recognized by the surface receptors on TEC cells.
Alternatively, in the complete absence of OPN, OPN-/- TECs may have altered or
reduced their levels of OPN receptors (CD44 and av(33 integrin receptors] and
would require even higher concentrations of rmOPN (beyond normal physiological
concentrations) to be responsive. Nonetheless, this data supports the notion that
OPN influences NK cell migration but through an indirect mechanism, requiring the
participation of the TEC to process OPN or to express other chemotactic proteins
such as chemokines. An approach to study OPN regulation of chemokines in TECs
would be to silence OPN in OPN+/+ TECs using RNA silencing technology against the
OPN gene. OPN silencing in TECs was attempted in this study, but was unsuccessful.
Alternatively, OPN's role in NK cell chemotaxis may also be clarified by blocking
known OPN receptors such as CD44 and cxvp3 integrins.
Based on our results, OPN likely regulates the chemotactic capacity of TECs
through an indirect mechanism(s). TECs have been shown on activation to produce
chemokines following inflammation or injury [167, 168).

Chemokines that are

relevant to NK cell attraction include MCP1, M IP la, IP-10, CX3CL1 and RANTES
which are also expressed by TECs [30,153]. OPN has been shown to induce MCP1,
M IP -la or MIP-1|3, RANTES in various inflammatory diseases and pathoses [169,
170]. Synovial fluids of rheumatoid arthritis patients have elevated levels of OPN.
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As well, CD14+ monocytes found in these sites produce high levels of MCP1 and MIPip , which could be attenuated by anti-human OPN antibodies [169]. Inflammatory
cytokines such as TGF-p, and TNF-a have been found to stimulate OPN production
and have a synergistic effect on chemokine production [144, 171]. Although our
experiments did not demonstrate up-regulation of a panel of chemokines, OPN had a
differential effect on chemokine mRNA expression in OPN+/+ and OPN-/- TECs
(Figure 7]. In repeated experiments, upregulation of chemokine mRNA transcripts
was observed in OPN-/- TECs above what was observed in OPN+/+ TECs in response
to rmOPN. While the relative lack of effect in OPN+/+ TECs may reflect high basal
levels of expression of OPN by OPN+/+ TECs and saturation of OPN receptors, these
findings support the notion that the moderate recovery of chemoattractive capacity
for NK cells by treated OPN-/- TECs was related to the expression of chemokines in
response to OPN (Figure 6], However, it should be noted that as mRNA and not
chemokine proteins were measured, this conclusion was inferred. Furthermore,
there may be other NK relevant chemokines expressed by TECs in response to OPN
which we did not measure.
Collectively, my results suggest that kidneys express abundant OPN following
IRI and TEC expressed OPN is likely a primary producer of kidney OPN, given that
75% of the renal cortex is composed of TEC. Based on the chemotaxis experiments,
TECs possess the ability to recruit NK cells (Fig. 4). Furthermore, OPN is able to
influence TEC's ability to recruit NK cells and produce NK chemokines (Fig. 6, 7).
Therefore, OPN may be an attractive therapeutic target as it bridges innate immune
regulation and kidney injury, particularly as it has been demonstrated that TECs can
be killed by NK cells [34,118].
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4.3
OPN Does Not Provide Survival Benefits to TEC When Treated with
Inflammatory Cytokines (TNF-a & IFN-y) and Hypoxia In Vitro
While OPN has the capacity to promote NK and other cell chemotaxis[118,
124-126, 131], and plays a role in worsening renal 1RI in vivo [117, 118], OPN has
diverse effects on cell survival that may make its expression desirable during
inflammation. OPN has been described as a pro-survival factor for many cell types
including: cancer cells, endothelial, T, DC, monocytes and macrophages [121, 123,
129-132]. To test if OPN acts as an anti-apoptosis agent on TECs, OPN'/- and OPN+/+
TECs were subjected to hypoxia and cytokines (TNF-a and IFN-y), at levels of
exposure known to cause cell death [40]. TNF-a and IFN-y induce TEC death and
Were used in conjunction with hypoxia to simulate the inflammatory and ischemic
injury transplant grafts experience [40]. Cell death were measured by combined AV
and PI labeling and quantified by flow cytometry. AV detects apoptotic cells by
binding to phosphatidylserines that have 'flipped' from the inner leaflet of the
plasma membrane to the surface of the cell. PI functions as a cell viability stain, by
intercalating between DNA bases.

PI cannot penetrate viable cell membranes.

Despite adequate exposure to death inducing stimulants, OPN did not provide any
significant benefit to TEC survival following hypoxia and or cytokine induced cell
death. Both OPN'/’ and OPN+/+ TECs showed similar changes in AV label (apoptosis),
PI label (necrosis) and double positive quadrants labeling (necro-apoptosis) (Figure
8). Similarly, supplementation with exogenous rmOPN did not provide survival
benefits to TECs when subjected to same levels of hypoxia and cytokines. These
results contrast to previous studies in which cell survival was enhanced [115,122]
and this may be due to differences in the cell type tested. Assays performed by other
groups used transformed cells, while ours used primary TEC cultures. A previous
study using transformed rat kidney epithelial cells used serum starvation (0.1%)
conditions and neutralizing OPN antibodies rather than OPN'/' TECs to test OPN as a
survival factor [122]. Therefore, differences in results may be due to the difference
in stress model or may be that OPN does not act to promote survival in all cell types
including TECs in this model. Although OPN may not provide a direct survival
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advantage to TECs during hypoxia and cytokine exposure in vitro, this may not
exclude a role for OPN in vivo where other parenchymal cells may respond to OPN to
improve organ survival post-IR.

4.4.

Absence o f OPN in Kidney Grafts Reduces Kidney Function and Survival in an
Allogenic Kidney Transplant Model
Given the fact that there was reduced kidney injury in OPN-/- kidneys in an in

vivo IRI model[118] and the chemotaxis of NK cells by TECs can be influenced by
OPN, it might be predicted that a lack of donor organ OPN could benefit transplants.
An in vivo mouse transplant model was used to test the role of OPN in kidney
allograft function and survival. A fully MHC mismatched allogenic kidney transplant
into nephrectomized recipients model was used. This model is stringent in that
bilateral nephrectomy unequivocally demonstrates function from the transplanted
kidney. Thus, the survival of the mouse is entirely dependent on the transplanted
kidney and there is no source of OPN from any remaining kidney tissue to alter the
results.
In contrast to IRI in which OPN deficiency resulted in reduced injury in a
mouse IRI model [118], in our transplant model, OPN-/- transplanted kidneys had
significantly higher serum creatinine levels (110.1 pmol/L ± 36.4 vs. 26 pmol/L ±
2.8, p < 0.019] (Figure 9A] and urea levels (49.0 mmol/L ± 14.4 vs. 20.4 mmol/L ±
2.0, p-value < 0.033] than OPN+/+ kidneys (Figure 9B] at the same time (day 8). OPN
deficiency in short term injury models such as IRI and UUO has reduced infiltrate
and injuiy. Again in contrast with short term injury models, and consistent with
serum creatinine levels, OPN-/- transplanted kidneys had a much higher overall
injury score (all the categories averaged] of 0.84 ± 0.045 S.E.M, when compared to
OPN+/+ kidneys that had a score of 0.44 ± 0.11 (p < 0.005] (Figure 10B]. Although
we did not find a survival benefit or attenuation of apoptosis in TECs in vitro (Figure
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8A, B], a potential explanation for our results may be due to increased cell death in
other cell types in the OPN-/- kidney grafts.
Greater TUNEL positive cells were observed in OPN-/' kidneys than
OPN+/+kidney (Figure 11C). Although there were more TUNEL positive cells found
in the OPN-/* kidney interstitium, it was not possible to clearly differentiate
infiltrating lymphocytes from TECs undergoing apoptosis.

Furthermore, OPN

deficiency in the interstitium may have influenced infiltrating cell survival and
function. It is known that OPN is a pluripotent protein that functions as a proinflammatory cytokine and chemokine [104,166]. However, OPN may have a role in
regulating the inflammatory responses by influencing the type of infiltrates that
accumulate in the kidney. A possible explanation for increased apoptosis along with
reduced kidney function in OPN-/- grafts may be related to the altered composition
of infiltrating cells.
Lymphocytes that infiltrate allografts include T cells, B cells, NK cells and
macrophages. We selected IHC to identify graft infiltrates. IHC was selected over
flow cytometry to correlate with hematoxylin and eosin data which showed greater
arteriole injury and to attempt to determine the infiltrate phenotypes at this
location. Furthermore, flow cytometry requires a fair amount of cells for an accurate
measure and it is unclear if sufficient kidney infiltrates could be harvested per
transplant.
There appears to be more T cell infiltrates in OPN /- kidney grafts compared
to OPN+/+ by CD3 staining (Figure 11A). Although it would be have been more
informative to determine the presence of CD4+ or CD8+ T cells in the kidney
infiltrate, these results were hampered by technical hurdles as high resolution
stains were difficult to obtain on frozen sections due to high background staining
resulting from TEC’s abundant production of peroxidases.

Similarly, MAC-1 and

B220 stains on frozen sections were unable to show clear differences in macrophage
and B cell infiltrates between the two grafts.

Since OPN is known to act as a
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differentiation factor for certain immune cells, perhaps OPN-/- kidneys also have a
reduced ability to attract or promote regulatory immune cells. Tregs populations
were isolated from kidney graft infiltrates by purifying for CD4+CD25+FoxP3+ cells
in kidney grafts 8 days post transplantation (Figure 13). However, there was no
difference in Treg populations between the two organ types. It is appreciated that
while the FACS based phenotype of Tregs may be the same in both OPN+/+ and OPN/- kidney grafts, we did not test their ability to "function” as regulatory cells.
Since OPN exacerbates the severity of multiple sclerosis in mice [129] and
OPN promotes the survival and activation of macrophage, and T h l T cells[129,142,
172,173], I was not able to explain why the loss of OPN worsened inflammation in
kidney transplants. Future transplant experiments should include kidneys in which
RNA is silenced to rule out any potential artefact of OPN'é_ kidneys, as well as using
rmOPN administration into recipients after transplantation to test for reduced
inflammation, apoptotic infiltrates, and increased kidney function. As well, future
tests to quantify kidney infiltrates should include flow cytometry, but this may also
require a larger number of transplants to ensure sufficient cells for flow cytometry
analysis.

Using qPCR for specific lymphocyte genes may provide additional

qualitative support for the type of kidney infiltrate present.
Although OPN was not found to be a pro-survival factor for TECs in vitro, it
may be a different case for endothelial cells, since the destruction of the local
circulatory system would also result in the death of TECs. It has been documented
that endothelial cell regeneration in the carotid artery of rats is dependent on the
presence OPN [174],
OPN has also been known to be a repair and regeneration factor for cornea,
endothelium, and is a stimulating factor for macrophage phagocytosis [159, 173,
174]. If the phagocytic ability of macrophages to 'clean up’ debris has been reduced
in the OPN-/’ grafts, regeneration and repair would be hampered. Furthermore, OPN
has been known to act as an opsonin for macrophages which may also affect
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clearance of apoptotic or cellular debris [173],

Additionally, TECs can exert

phagocytic properties through KIM-1 expression, therefore, it may also be
reasonable to test whether OPN can alter TEC phagocytosis [48]. In short, gradual
accumulation of cellular debris or apoptotic cells may perpetuate inflammation by
stimulating TECs to release pro-inflammatory agents, recruit innate immune cells
and produce secondary necrosis ([175-177], reviewed in [178]). Therefore, if OPN’éTECs have reduced ability to phagocytize pro-inflammatory cellular debris, it may
be a reason for the reduced kidney function and survival of the OPN'/- kidney grafts.

4.5.

Conclusion
OPN is regarded as a potential target for neutralization in order to reduce

disease and injuiy severity [129, 132,169]. For acute kidney injury during 1RI, we
believe that OPN may in part potentiate injury by acting as an indirect regulator of
NK chemokine expression in TECs. However, full NK chemokine protein analysis is
needed to further solidify this claim.
This study also offers a different perspective on OPN as a potential
therapeutic target in regard to transplantation. The data from this study suggests
that while OPN neutralization may prove beneficial to reduce short term injury such
as IRI, complete loss of donor organ OPN in the context of transplantation results in
worse inflammation, reduced graft survival and function. Thus, future use of antiOPN therapeutic agents will require a balance between the beneficial effects gained
from loss of OPN during IRI and the detrimental effects on inflammation and graft
survival as well as long term healing. Clearly, further investigation is required to
understand OPN’s role as an inflammatory regulator, regeneration and repair factor
in a kidney transplant chronic injury model.
Taken together, OPN clearly has a complex role in kidney inflammatory
injury and further in depth study is necessary before OPN can be used efficiently as
a therapeutic target. Some key studies may include the determination of OPN’s
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effect on a Treg cell's ability to function as a regulatory cell and OPN as a
regeneration and repair factor for TECs.

Furthermore, it may be interesting to

determine the significance of systemic expression of OPN on graft rejection, by
transplanting OPN+/+ kidney grafts into an OPN-/- recipient. Ultimately, these
experiments will add valuable insight to this study's findings and provide important
future considerations for therapeutic strategies in renal transplantation that involve
manipulation of OPN.
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